Cover Page  for Protocol  
Sponsor name:  [CONTACT_3454] A/S  
NCT number  [STUDY_ID_REMOVED]  
Sponsor t rial ID:  NN9535 -4321  
Official title of study:  FLOW – Effect of Semaglutide  versus Placebo on the 
Progression of Renal Impairment in Subjects with Type 2 
Diabetes and Chronic Kidney Disease  
Document date:  25 January 2021  
*Document date refers to the date on which the document was most recently updated.
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
Status:  Final  
Page:  1 of 88 
Protocol
Including:  
amendment 1 (Argentina), 2 ([LOCATION_013])  and 3 (India) , dated 11 November 2020 , protocol version 
4.0 
amendment 4 (all countries) , dated  03 November 20 20, protocol version 3.0 
amendment 5 (China), dated 25 January 2021, protocol version 5.0  
Protocol title: FLOW - Effect of semaglutide versus placebo on the 
progression of renal impairment in subjects with type 2 diabetes and 
chronic kidney disease
Substance name: [CONTACT_687328]: U1111 -[ADDRESS_931529] Number: 2018 -002878 -50 
Trial phase: 3b  
In the following, Novo Nordisk A/S and its affiliates will be stated as “Novo Nordisk”.  
                
                 
 
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  2 of 88 
 
Protocol amendment summary of changes table   
DOCUMENT HISTORY  
Document  Date  Version  
Updated protocol including 
amendment 5 (China)  25 January 2021  5.0 
Updated protocol including 
amendment 1 (Argentina), 2 
([LOCATION_013]), 3 (India)   11 November 2020  4.0 (includes all amendments from 
1-4) 
Updated protocol including 
amendment 4 (all countries)  03 November 2020  3.0 
Original protocol  07 December 2018  2.0 (version 1 .0 was never part of a 
CTA submission ) 
Protocol amendment no. 5 (dated 25 January 2021, included in version 5.0)  
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Uni on.[ADDRESS_931530] patient safety.  
Section # and name  [CONTACT_687329] 8                            
Country -specific requirements for 
China, amendment 5  The following change is not 
applicable for China : Section 6.2, 
exclusion criteria  #4: *Simultaneous 
participation in a trial with the 
primary objective of evaluating an 
approved or non -approved 
investigational medicinal product for 
prevention or treatment of COVID -[ADDRESS_931531] has 
been received more than 30 days 
before screening  Co-participation in COVID -19 
trials  is not allowed in China due 
to local requirements  
Appendix 8                            
Country -specific requirements for 
China, amend ment 5  The following change is not 
applicable for China : Section 8.1, 
discontinuation/withdrawal criteria: 
*Simultaneous participation in a trial 
with the primary objective of 
evaluating an approved or non -
approved investigational medicinal 
product for pre vention or treatment of 
COVID -[ADDRESS_931532]  Co-participation in COVID -19 
trials  is not allowed in China due 
to local requirements  
Appendix 10                            
Protocol amendment history, 
amendment 5 Previous protocol amendments 
relocate in Appendix 10  To align with internal SOP  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  3 of 88 
 
Table of Contents     
Protocol amendment summary of changes table  ................................ ................................ ...........................  2 
1 Synopsis  ................................ ................................ ................................ ................................ ......................  6 
2 Flowchart  ................................ ................................ ................................ ................................ ...................  8 
2.1 Flowchart explanatory descriptions  ................................ ................................ .............................  11 
3 Introduction  ................................ ................................ ................................ ................................ .............  12 
3.1 Trial rational e ................................ ................................ ................................ ...............................  12 
3.2 Background  ................................ ................................ ................................ ................................ .. 12 
3.3 Benefit -risk assessment  ................................ ................................ ................................ ................  13 
3.3.1  Benefits related to semaglutide  ................................ ................................ ..................  13 
3.3.2  Risks related to semaglutide  ................................ ................................ ......................  13 
3.3.3  Risk-benefit conclusion  ................................ ................................ .............................  15 
4 Objectives and endpoints  ................................ ................................ ................................ ........................  16 
4.1 Primary, secondary and exploratory objectives  ................................ ................................ ...........  16 
4.2 Primary, secondary and exploratory endpoints  ................................ ................................ ............  16 
4.2.1  Primary endpoint  ................................ ................................ ................................ ........  16 
4.2.2  Secondary endpoints  ................................ ................................ ................................ .. 16 
[IP_ADDRESS]  Confirmatory secondary endpoints  ................................ .....................  16 
[IP_ADDRESS]  Supportive secondary endpoints  ................................ ..........................  [ADDRESS_931533] and trial completion  ................................ ................................ ................................ ........  19 
5.3 End of trial definition  ................................ ................................ ................................ ...................  20 
5.4 Scientific rationale for trial design  ................................ ................................ ...............................  20 
5.5 Justification for dose  ................................ ................................ ................................ ....................  21 
6 Trial population  ................................ ................................ ................................ ................................ ....... 22 
6.1 Inclusion criteria  ................................ ................................ ................................ ..........................  22 
6.2 Exclusion criteria  ................................ ................................ ................................ .........................  22 
6.3 Lifestyle restrictions  ................................ ................................ ................................ ....................  23 
6.4 Screen failures  ................................ ................................ ................................ ..............................  23 
6.5 Randomisation criteria  ................................ ................................ ................................ .................  24 
7 Treatments  ................................ ................................ ................................ ................................ ...............  25 
7.1 Treatments administered  ................................ ................................ ................................ ..............  25 
7.1.1  Medical devices  ................................ ................................ ................................ .........  25 
7.2 Dose modification  ................................ ................................ ................................ ........................  25 
7.2.1  Missed doses  ................................ ................................ ................................ ..............  26 
7.3 Method of treatment assignment  ................................ ................................ ................................ .. 26 
7.4 Blinding  ................................ ................................ ................................ ................................ ....... 26 
7.5 Preparation/Handling/Storage/Accountability  ................................ ................................ .............  27 
7.6 Treatment compliance  ................................ ................................ ................................ ..................  28 
7.7 Conc omitant medication  ................................ ................................ ................................ ..............  28 
7.8 Treatment after the end of the trial  ................................ ................................ ..............................  29 
8 Discontinuation/Withdrawal criteria  ................................ ................................ ................................ .... [ADDRESS_931534] to follow -up ................................ ................................ ................................ .........................  31 
9 Trial asse ssments and procedures  ................................ ................................ ................................ .........  33 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  4 of 88 
 
9.1 Optional pre -screening  ................................ ................................ ................................ .................  33 
9.2 Efficacy assessments  ................................ ................................ ................................ ....................  34 
9.2.1  Self-measured plasma glucose  ................................ ................................ ...................  34 
9.2.2  Clinical efficacy laboratory assessments  ................................ ................................ ... 34 
9.2.3  Patient reported outcomes  ................................ ................................ ..........................  35 
9.3 Adverse events  ................................ ................................ ................................ .............................  35 
9.3.1  Time period and frequency for collecting AE and SAE information  ........................  35 
[IP_ADDRESS]  Events for adjudication  ................................ ................................ ........  38 
9.3.2  Method of detecting AEs and SAEs  ................................ ................................ ..........  39 
9.3.3  Follow -up on AEs and SAEs  ................................ ................................ .....................  39 
9.3.4  Regulatory reporting requirements for SAEs ................................ .............................  39 
9.3.5  Cardiovascular and death events  ................................ ................................ ................  40 
9.3.6  Disease -related events and/or disease -related outcomes not qualifying as an AE 
or SAE ................................ ................................ ................................ ........................  40 
9.3.7  Pregnancies and associated adverse events  ................................ ................................  40 
9.3.8  Medical device incidents (including malfunctions)  ................................ ...................  41 
9.3.9  Technica l complaints  ................................ ................................ ................................ . 41 
9.4 Treatment of overdose  ................................ ................................ ................................ .................  42 
9.5 Safety assessments  ................................ ................................ ................................ .......................  42 
9.5.1  Phys ical examinations  ................................ ................................ ................................  43 
9.5.2  Vital signs  ................................ ................................ ................................ ..................  43 
9.5.3  Eye examination  ................................ ................................ ................................ ........  44 
9.5.4  Clinic al safety laboratory assessments  ................................ ................................ ....... 44 
9.6 Pharmacokinetics  ................................ ................................ ................................ .........................  44 
9.7 Pharmacodynamics  ................................ ................................ ................................ ......................  44 
9.8 Genetics  ................................ ................................ ................................ ................................ ....... 45 
9.9 Biomarkers  ................................ ................................ ................................ ................................ ... 45 
10 Statistical considerations  ................................ ................................ ................................ ........................  46 
10.1  Sample size determination  ................................ ................................ ................................ ...........  46 
10.2  Definition of analysis sets  ................................ ................................ ................................ ............  47 
10.3  Statistical analyses  ................................ ................................ ................................ .......................  47 
10.3.1  Primary endpoint  ................................ ................................ ................................ ........  48 
10.3.2  Secondary endpoints  ................................ ................................ ................................ .. 49 
[IP_ADDRESS]  Confirmatory secondary endpoints  ................................ .....................  49 
[IP_ADDRESS]  Supportive secondary endpoints  ................................ ..........................  50 
10.3.3  Exploratory endpoints  ................................ ................................ ................................  51 
10.3.4  Interim testing for efficacy ................................ ................................ .........................  51 
10.3.5  Sequential safety analysis and safety monitoring  ................................ ......................  51 
10.4  Pharmacokinetic and/or pharmacodynamic modelling  ................................ ................................  51 
11 References  ................................ ................................ ................................ ................................ ................  52 
12 Appendices  ................................ ................................ ................................ ................................ ...............  54 
Appendix 1  Abbreviations and Trademarks ................................ ................................ ..............  55 
Appendix 2  Clinical laboratory tests  ................................ ................................ ..........................  57 
Appendix 3  Trial governance considerations  ................................ ................................ .............  59 
Appendix 4  Adverse events: definitions and procedures for recording, evaluation, 
follow -up, and reporting  ................................ ................................ .........................  68 
Appendix 5  Contraceptive guidance and collection of pregnancy information  ......................  72 
Appendix 6  Technical complaints: Definition and procedures for recording, evaluation, 
follow -up and reporting  ................................ ................................ ..........................  75 
Appendix 7  Retention of human biosamples  ................................ ................................ ..............  77 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  [ADDRESS_931535] safety and data integrity during 
epi[INVESTIGATOR_7509]/pandemics (e.g. COVID -19) ................................ ................................ .. [ADDRESS_931536] of key staff and relevant departments  
 
 
 
 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  6 of 88 
 
1 Synopsis   
Rationale  
Chronic kidney disease (CKD) and diabetes often co -exist and for the majority of cases, the kidney 
damage and/or reduced kidney function is caused directly by [CONTACT_687287]. Improved glycaemic control has been suggested  to red uce the progression of CKD in type 
2 diabetes (T2D) and both glycaemic and blood pressure control are key recommendations in 
international treatment guidelines for CKD in T2D. Yet there remains a major unmet medical need 
to improve the treatment of CKD in patients with T2D. The purpose of this trial is to demonstrate 
that semaglutide subcutaneously  (s.c.) delays the progression of renal impairment and lowers the 
risk of renal and cardiovascular (CV) mortality in subjects with T2D and CKD.  
Objectives and endpoints  
The primary objective  is to demonstrate that semaglutide delays the progression of renal 
impairment and lowers the risk of renal and cardiovascular mortality compared to placebo, both 
added to standard -of-care, in subjects with type [ADDRESS_931537] occurrence of a composite endpoint consisting of: Onset of 
persistent ≥ 50% reduction in estimated glomerular filtration rate (eGFR)  (CKD -EPI) compared 
with baseline , onset of persistent eGFR  (CKD -EPI) < 15 mL/min/1.73 m2, initiation of chronic 
renal replacement therapy  (dialysis or kidney transplantation) , renal death, or cardiovascular death.  
The key secondary endpoints  are annual rate of change in eGFR  (CKD -EPI) (total eGFR slope), 
time to first occurrence of a composite  major adverse cardiovascular event ( MACE ) endpoint 
(consisting of: non -fatal myocardial infarction, non -fatal stroke, CV death) and all-cause death.  
The estimand  for all objectives is based on the intention -to-treat principle evaluating the effect of 
the randomised treatment intervention irrespective of adherence to this and changes to background 
medication.  
Overall design  
This is a multi -centre, inter national, randomised, double -blind, parallel -group, placebo -controlled 
trial comparing semaglutide 1.[ADDRESS_931538] -of-care in subjects with T2D and pre -existing CKD. Subjects will be randomised  1:1 to 
receive either semaglutide or placebo . Randomisation will be stratified by [CONTACT_687288] -2 (SGLT -2) inhibitors (yes  versus no) at baseline.  The number of subjects with 
inclusion eGFR ≥ 60 mL/min/1.73 m2 will be capped at 20%.  
Key inclusion criteria  
• Male or female, age ≥ 18 years at the time of signing informed consent. Japan: For country 
specific requirements, please see Appendix 8 .  
• Diagnosed with type 2 diabetes mellitus  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
Status:  Final  
Page:  7 of 88 
•HbA 1c ≤ 10% (≤ 86 mmol/mol)
•Renal impairment defined either by :
a)serum creatinine -based eGFR ≥ 50 and ≤  75 mL/min/1.73 m2 (CKD -EPI) and UACR > 300
and < 5000  mg/g
or 
b)serum creatinine -based eGFR ≥ 25 and <  50 mL/min/1.73 m2 (CKD -EPI) and UACR > 100
and < 5000 mg/g
•Treatment with maxim um labelled or tolerated dose of a renin -angiotensin -aldosterone system
(RAAS ) blocking agent including an angiotensin converting enzyme (ACE ) inhibitor or an
angiotensin II receptor blocker  (ARB ), unless such treatment is contraindicated or not tolerated .
Treatment dose must be stable for at least  4 weeks prior to the date of the laboratory
assessments used for  determination of the inclusion criteria for renal impairment  and kept stable
until screening .
Key exclusion criteria  
•Congenital or hereditary kidney diseases including polycystic kidney disease, autoimmune
kidney diseases including glomerulonephritis or congenital urinary tract malformations
•Use of any glucagon -like peptide -1 (GLP -1) receptor agonist within 30 days prior to screening
•Myocardial infarction, stroke, hospi[INVESTIGATOR_687278] 60 days pr ior to the day of screening
•Presently classified as being in [LOCATION_001] Heart Association (NYHA) Class IV heart failure
•Planned coronary, carotid or peripheral artery revascularisation
•Current (or within 90 days) chronic  or intermittent haemodialysis or peri toneal dialysis
•Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus
examination performed within the past [ADDRESS_931539].  
Treatment groups and duration  
The trial is event driven  and includes  a pre -defined minimum number of renal endpoint events ; 
therefore, end of trial will be scheduled according to projected trial closure. Trial duration from the 
first subject visit is expected to be [ADDRESS_931540] is expected to be approximately 3 to 5 years.  
The trial products are:  
•Active trial product: Semaglutide 1.34 mg/mL, solution for injection.
•Semaglutide placebo, solut ion for injection.
CONFIDENTIAL
VV-CLIN-281603 1.0 .
VV-CLIN-281603 1.0 .
VV-CLIN-281603 1.0 .
VV-CLIN-281603 1.0 .
Protocol  Date:  25 January 2021  Status:  Final  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 Page:  11 of 88 
h Only at year 2 and 3 (week 104 and 156)  
i Only at year 3 (week 156)  
j Only applicable for women of childbearing potential; urine HCG.  
kThe yearly visits should take place approximately 13 weeks after the previous visit 
2.1 Flowchart explanatory descriptions  
As individual follow u p time will differ depending on enrolment date, visits in the treatment maintenance period will be added or removed depending  on 
time of randomisation and trial closure timing.  
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
Status:  Final  
Page:  [ADDRESS_931541] of 
the clinical trial at a trial site.  
3.1 Trial rationale  
Chronic kidney disease  (CKD) and diabetes often co -exist and for the majority of cases  the kidney 
damage and/or reduced kidney function is caused directly by [CONTACT_687287]. Up to 40% of patients with type 2 diabetes (T2D) have some degree of CKD, a nd diabetes 
is the single leading cause of end -stage renal disease (ESRD) requiring chronic dialysis  treatment  or 
kidney transplantation.2 Improved glycaemic control has been suggested  to reduce the development 
and progression of CKD i n T2D3, 4 and both glycaemic and blood pressure control are key 
recommenda tions in international treatment guidelines for CKD in T2D.5 Blocking the renin -
angiotensin -aldostero ne system (RAAS) with angiotensin -converting -enzyme inhibitors (ACE 
inhibitors) or angiotensin II receptor blockers (ARBs) for the treatment of CKD in patients with 
T2D and increased levels of albuminuria is recommended as first -line therapy and some of th e 
RAAS blocking agents (irbesartan6, losartan7 and captopril8) have a labelled indication for the 
treatment of CKD in diabetes .5 However, up to 70% of the patients with T2D and CKD experience 
continued deterioration of the kidney function despi[INVESTIGATOR_687279].9-[ADDRESS_931542]. The aim of the current trial is to demonstrate that treatment with o nce 
weekly semaglutide subcutaneously  (s.c.) delays the progression of renal impairment and lowers the 
risk of renal and cardiovascular mortality in subjects with T2D and CKD.  
3.2 Background  
Recently conducted clinical trials with the glucagon -like peptide -1 (GLP -1) receptor agonists 
semaglutide, liraglutide, dulaglutide, and exenatide have suggested a  possible  renoprotective effect 
in patients with T2D, CKD and high cardiovascular (CV) risk.12-[ADDRESS_931543] on 
new or worsening nephropathy in patients with T2D and established or high risk for CV disease has 
also been sugge sted17-19 in another class of glucose lowering drugs; the  sodium glucose 
cotransporter -2 (SGLT -2) inhibitors, and dedicated renal outcomes trials are currently  running or 
have been announced for empagliflozin20 and dapagliflozin (Study Registry ID: [REMOVED]) . In addition, the CREDENCE renal outcomes trial with canagliflozin 
(Study Registry ID: [REMOVED]) was stopped early based on the achievement of pre -
specified efficacy criteria at a pre -planned interim analysis.  
The current trial will include subjects with T2D and established CKD defined by [CONTACT_687289] -to-creatinine ratio ( UACR ) and reduced  estimated glomerular filtration rate  (eGFR ). These 
enrichment criteria are selected as reduced eGFR and increased UACR have been shown to be 
independent risk factors for progression of renal impa irment and development of ESRD.21 Thus, a 
population of subjects with T2D and primarily moderate CKD and increased UACR is considered 
an appropriate target population for a risk reduction intervention and will ensure that the primary 
objective of the trial can be m et within a reasonable timeframe and sample size. The number of 
subjects with inclusion  eGFR values in the high end of the eGFR range , i.e. eGFR ≥ 60 
mL/min/1.73 m2, will be capped at 20% to ensure a sufficient event rate for the primary endpoint, as 
the e vent rate is expected to be lower in these subjects.   
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
Status:  Final  
Page:  [ADDRESS_931544] 
severely  increased albuminuria at enrolment. Communications to sites may be used over the course 
of the recruitment period to focus recruitment efforts on patients with high risk for CKD 
progression without restricting the enrolment of any eligible subgrou ps.  
Detailed information for semaglutide s.c. is available in the current edition and any updates of the 
Investigator’s Brochure.  
3.[ADDRESS_931545] adequate glycaemic control, 
investigators are encouraged to optimise treatment with anti -hyperglycaemic medications (GLP -1 
receptor agonists  excluded) throug hout the trial in accordance with local clinical practice. All 
subjects  in this trial will receive trial product and auxiliary supplies free of charge.  
3.3.2 Risks related to semaglutide  
Identified risks  
Based on the clinical development programme a causal relationship with semaglutide was suggested 
for the following risks:  
Gastrointestinal disorders: For semaglutide as for other GLP -[ADDRESS_931546] 
frequently reported adv erse reactions in clinical trials were gastrointestinal (GI) disorders, including 
nausea, diarrhoea and vomiting. In general, these reactions were mild or moderate in severity and of 
short duration. A dose dependency has been observed for most of the GI di sorders. Clinical trials 
have shown that a low starting dose and gradual dose escalation mitigates the risk of GI adverse 
events ( AEs).  
In patients treated with GLP -1 receptor agonists, nausea, vomiting and diarrhoea may lead to 
significant dehydration. This should be considered when treating patients with impaired renal 
function as it may lead to further deterioration of renal function. Subjects with GI AEs are 
recommended to drink plenty of fluids, unless medically contraindicated, to avoid volume 
deple tion. 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
Status:  Final  
Page:  14 of 88 
Hypoglycaemia: Patients treated with semaglutide in combination with a sulfonylurea or insulin 
may have an increased risk of hypoglycaemia compared to patients treated with semaglutide as 
monotherapy or in combination with other anti -hyperglycaemic  medications. The risk of 
hypoglycaemia can be lowered by [CONTACT_687290].  
Diabetic retinopathy complications: Adjudicated events of diabetic retinopathy complications 
occurred in more p atients treated with semaglutide (3.0%) when compared to placebo (1.8%) in a 2 -
year clinical trial involving 3,297 subjects with T2D and high CV risk, long duration of diabetes 
and poor glycaemic control. Diabetic retinopathy complications were a composite  of: need for 
retinal photocoagulation, need for treatment with intravitreal agents, vitreous haemorrhage and 
onset of diabetes -related blindness. The absolute risk increase for diabetic retinopathy 
complications was greatest among patients with a history of diabetic retinopathy at baseline. In 
patients who did not have a documented history of diabetic retinopathy, the number of events was 
similar for semaglutide and placebo.  
In other clinical trials of up to 1 year duration involving 4,807 subjects with T 2D, AEs related to 
diabetic retinopathy were  distributed  similarly between subjects treated with semaglutide (1.7%) 
and comparators (2.0%).  
Rapid improvement in glycaemic control, for example with insulin, has been associated with a 
temporary worsening of diabetic retinopathy. Long -term sufficient glycaemic control decreases the 
risk of diabetic retinopathy. Subjects with a history of diabetic retinopathy should be monitored for 
worsening and treated according to clinical guidelines.  
Other risks: Patients t reated with semaglutide may also experience cholelithiasis, decreased 
appetite, dizziness, dysgeusia, fatigue, increased heart rate, increased lipase and amylase, injection 
site reactions and weight decrease.  
Potential risks  
A possible association with sem aglutide has been suspected for the following risks, although the 
relationship has not yet been confirmed:  
Allergic reactions: As in the case with all protein -based pharmaceuticals, treatment with 
semaglutide may evoke allergic reactions, including serious  allergic reactions such as anaphylactic 
reactions.  
Acute pancreatitis: Acute pancreatitis has been observed with the use of GLP -1 receptor agonists. 
Patients should be informed of the characteristic symptoms of acute pancreatitis and if pancreatitis 
is suspected, semaglutide should be discontinued. If confirmed, semaglutide should not be restarted.  
Malignant neoplasms: Based on available data, there is no indication of a causal relationship 
between semaglutide and malignant neoplasms. However, it is not possible to draw any firm 
conclusions due to very low numbers.  
Pancreatic cancer: Patients with T2D have an increased risk of certain types of cancer such as 
pancreatic cancer. In the development programme, rates of pancreatic cancer were low and do 
not support a causal association with semaglutide. Furthermore, no safety concerns relat ed to 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
Status:  Final  
Page:  [ADDRESS_931547] s 
by [CONTACT_17513].  
Medullary thyroid cancer: Thyroid C -cell tumours were seen in mice and rat carcinogenicity 
studies after daily exposure to semaglutide for 2 years. The rodent C -cell tumours are caused by 
a non -genotoxic, specific GLP -1 receptor mediated mechanism to which rodents are particularly 
sensitive . No C -cell tumours were observed in monkeys after 52 weeks of exposure up to 27 -
fold above the clinical plasma exposure at 1.0 mg/week. The GLP -1 receptor is not expressed in 
the normal human thyroid and the risk of GLP -1 receptor -mediated C -cell changes in humans is 
considered to be low.  
Other safety considerations  
Drug interactions : Semaglutide delays gastric emptying and has the potential to impact the rate of 
absorption of concomitantly administered oral medicinal products. The potential effect of 
sema glutide on the absorption of co -administered oral medications was studied in trials at 
semaglutide 1 mg/week steady state exposure. No clinically relevant drug -drug interactions with 
semaglutide were observed based on the evaluated medications.  
Semaglutid e did not change the overall pharmacodynamics of warfarin as measured by [CONTACT_687291] (INR). However, upon initiation of semaglutide treatment in patients 
on warfarin and/or coumarin derivatives, frequent monitoring of INR is recommen ded. 
Pregnancy, lactation and fertility: Studies in animals have shown reproductive toxicity. There are 
limited data from the use of semaglutide in pregnant women. Therefore, semaglutide should not be 
used during pregnancy. If a subject  wishes to become pr egnant, or pregnancy occurs, semaglutide 
should be discontinued , see Appendix [ADDRESS_931548] -of-
care treatment will be provided throughout the trial. It is therefore concluded that the potential 
benefits from trial participation will outweigh the potential risks for the semaglutide as well as the 
placebo treated subjects . 
More detailed information about t he known and expected benefits and risks and reasonably 
expected AEs of semaglutide may be found in the Investigator’s Brochure.  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
VV-CLIN-281603 1.0 .
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
Status:  Final  
Page:  18 of 88 
a End-of-trial: a period expected to be up to [ADDRESS_931549]. Abbreviations: CKD -EPI, 
chronic kidney disease - epi[INVESTIGATOR_8261] ; CV, cardiovascular; eGFR, estimated glomerular filtration rate; 
EQ-5D-5L, five -level version of the EuroQol five -dimensional questionnaire; MACE, major adverse cardiovascular 
event; UACR, urinary albumin -to-creatinine ratio.  
Definition of terms  
When classifying chronic renal replacement therapy or kidney transplantation, the date of event 
should be the date of initiation of the therapy or surgery, respectively. The baseline for eGFR is 
defined as the mean of the two assessments from the screening  visit (V1) and the randomisation 
visit (V2).  
eGFR will be calculated using the chronic kidney disease – epi[INVESTIGATOR_8261] (CKD -EPI) 
formula.24 Sustained kidney failure is d efined as persistent eGFR < 15 mL/min/1.[ADDRESS_931550] sample meeting the 
definition.  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
Status:  Final  
Page:  19 of 88 
5 Trial design  
5.1 Overall design  
This is a multi -centre, international, randomised, double -blind, parallel -group, placebo -controlled 
trial comparing semaglutide  1.0 mg  versus placebo both administered s.c. once weekly 
(subsequently referred to as semaglutide and placebo) and added to standard -of-care in subjects 
with T2D and pre -existing CKD. Subjects will be randomised 1:1 to receive either semaglutide or 
placebo. Random isation will be stratified by [CONTACT_23265] -2 inhibitor use at baseline (yes versus no). The 
number of subjects with inclusion eGFR ≥ 60 mL/min/1.73 m2 will be capped at 20%.  
The trial is event driven  with a pre -defined minimum number of renal endpoint events (all 
components of the primary composite endpoint except CV death) for the primary endpoint . The trial 
will employ a group sequential design and interim testing for efficacy will be performed by a n 
independent external Data Monitoring Committee (DMC). The DMC will provide recommendation 
on trial continuation, modification or termination.  The observed number  and type  of confirmed 
primary endpoint events will be monitored throughout the trial . If the  trial is not stopped for 
efficacy at a planned interim testing  the trial will be terminated when both of the following criteria 
are fulfilled:  
•A minimum of 8 54 primary endpoint event s
•A minimum of [ADDRESS_931551] data for all randomised subjects.  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
Status:  Final  
Page:  [ADDRESS_931552]  
Trial period completion is defined as:  
•when the randomised subject has completed the final scheduled visit (follow -up visit according
to the flowchart).
or 
•when the randomised subject has died during trial.
Treatment period completion for a subject  
Treatment period completion is defined as when the randomised subject has received the required 
treatment and attended the end of treatment visit , according to the flowchart.  
The trial is event driven; therefore, end of treatment and follow -up visit  will be scheduled according 
to projected trial closure. When the trial is approaching the end investigators will be notified and 
instructed by [CONTACT_687292].  
When the trial comes to an end, the investigator must make every effort to ascertain efficacy and 
safety endpoint data for all subjects. This should be done by [CONTACT_687293]. If a subject proves difficult to reach for the follow -up visit, all attempts to re -
establish direct contact [CONTACT_687294] (see section  8.3). In case several attempts are required to 
establish direct contact [CONTACT_1639] a subject, exceeding the visit window of the follow -up visit may be 
needed. In order for the data set to be as complete as possible, end of trial follow -up information 
can be collected  until the randomisation codes are broken. If allowed by [CONTACT_427], 
publically available data sources may also be searched for withdrawn subjects in order to determine 
their vital status.   
5.[ADDRESS_931553] spectrum of concomitant anti -hyperglycaem ic medication, as well as 
treatments for comorbidities, CKD and CV risk factors can be introduced or adjusted throughout the 
trial based on individual requirements and at investigator’s discretion. This is in accordance with a 
pragmatic approach to compare  two treatments: one where semaglutide is available and another 
where it is not.  
To support the subject during the dose escalation period, site visits will occur more frequently 
during the first months of the trial. To maximise retention and compliance an d to optimise treatment 
and safety the subject is in contact [CONTACT_687295] 13th week throughout the trial. A 
multinational design has been chosen to ensure a sufficient screening pool of subjects and to reflect 
the anticipated global target p opulation  and ensure generalisability . The long half -life of 
semaglutide supports once weekly administration and the 5 -week follow -up is considered 
appropriate to the time that semaglutide remains in circulation.  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
Status:  Final  
Page:  [ADDRESS_931554] a positive benefit risk profile. Further, the benefit risk 
profile for the 1.0 mg dose was evaluated to be favourable over the 0.5 mg dose with lower 
proportions of subjects having a renal event in SUSTAIN 6. For informa tion regarding dose 
modifications, see Section 7.2. 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
Status:  Final  
Page:  22 of 88 
6 Trial population  
Prospective approval of protocol deviations to recruitment and enrolment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
6.1 Inclusion criteria   
Subjects a re eligible to be included in the trial only if all of the following criteria apply:  
1.Informed consent obtained before any trial -related activities. Trial -related activities are any
procedures that are carried out as part of the trial, including activities to determine suitability for
the trial , except for protocol described pre -screening activities which require a separate
informed consent.
2.Male or female, age above or equal to 18 years at the time of signing informed consent. Japan:
For country specific re quirements, please see Appendix 8 .
3.Diagnosed with type 2 diabetes mellitus.
4.HbA 1c ≤ 10% (≤ 86 mmol/mol)*.
5.Renal impairment defined either by :
a.serum creatinine -based eGFR ≥ 50 and ≤  75 mL/min/1.73 m2 (CKD -EPI)*, ** and
UACR > 300  and < 5000 mg/g.*
or 
b.serum creatinine -based eGFR ≥ 25 and <  50 mL/min/1.73 m2(CKD -EPI)* and
UACR > 100 and < 5000 mg/g.*
6.Treatment with  maximum labelled or tolerated dose of a renin -angiotensin -aldosterone  system
(RAAS ) blocking agent including an angiotensin converting enzyme (ACE ) inhibitor or an
angiotensin II receptor blocker  (ARB ), unless such treatment is contraindicated or not tole rated.
Treatment dose must be stable for at least 4 weeks prior to the date of the laboratory
assessments used for determination of inclusion criterion 5 and kept stable until screening.
* Laboratory results for inclusion can be  based on:
•measurements  no m ore than 90 days  old at screening , documented in medical records or
•measurement s from the optional pre -screening visit  (see Section  9.1), documented in medical
records or
•central laboratory measurement obtained at the screening visit
The subject must have been/be in usual health condition at the time of sample collection used for 
inclusion as eval uated by [CONTACT_687296]  a RAAS blocking agent, according to 
inclusion criterion 6. See Appendix 2  for all  requirements regarding clinical laboratory tests.  
** The number of subjects with inclusion eGFR ≥ 60 mL/min/1.73 m2 will be capped at 20% of 
randomised subjects.  
6.2 Exclusion criteria   
Subjects are excluded from the trial if any of the following criteria apply:  
1.Known or suspected hypersensitivity to trial product(s) or related products.
2.Previous participation in  this trial. Participation is defined as randomisation .
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
Status:  Final  
Page:  [ADDRESS_931555] -feeding or intends to become pregnant or is of child -bearing
potential and not using a highly effective  contraceptive method  (see Appendix 5 ).
4.Participation in any clinical trial of an approved or non -approved investigational medicinal
product within 30 days before screening *. Brazil: For country specific requirements, please see
Appendix 8 .
5.Any disorder, which in the investigator’s opi[INVESTIGATOR_36174]’s safety or
compliance with the protocol.
6.Congenital or hereditary kidney diseases including polycystic kidney dise ase, autoimmune
kidney diseases including glomerulonephritis or congenital urinary tract malformations.
7.Use of any GLP -[ADDRESS_931556] degree relative(s) history of multiple endocrine neoplasia type 2  (MEN2) or
medullary thyroid carcinoma (MTC).
9.Myocardial infarction, stroke, hospi[INVESTIGATOR_687278] 60 days prior to the day of screening.
10.Presently classified as being in [LOCATION_001] Heart Associatio n (NYHA) Class IV heart failure.
11.Planned coronary, carotid or peripheral artery revascularisation.
12.Current (or within 90 days ) chronic or intermittent haemodialysis or peritoneal dialysis.
13.Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus
examination performed within the past 90 days prior to screening or in the period between
screening and randomisation. Pharmacological pupil -dilation is a requirement unless using a
digital fundus photography camera specif ied for non -dilated examination.
14.Presence or history of malignant neoplasm within 5 years prior to the day of screening. Basal
and squamous cell skin cancer and any carcinoma in-situ are allowed.
15.A prior solid organ transplant or awaiting solid organ trans plant.
16.Combination use of an angiotensin converting enzyme ( ACE ) inhibitor and an angiotensin II
receptor blocker ( ARB ).
*Simultaneous participation in a trial with the primary objective of evaluating an approved or non -
approved investigational medicinal product for prevention or treatment of COVID -[ADDRESS_931557] has
been received more than 30 days before screening.
6.3 Lifestyle restrictions  
Not applicable for this trial. 
6.4 Screen failures  
Screen failures are defined as subjects who consent to participate in the clinical trial , but are not 
eligible for participation according to in/exclusion criteria. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure subjects to meet 
requirements from regulatory authorities. Minimal information includes demography, screen failure 
details, and eligibility criteria. A screen failure session must be made in the IWRS for subjects who 
are not randomised.  
Re-screening of previous screen failures is allowed twice in case the investi gator assesses that 
potential changeable or fluctuating in - or exclusion criteria may have changed (e.g. biochemical 
parameters (eGFR, UACR and HbA 1c) or ch ange in concomitant medication ). Previously 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
Status:  Final  
Page:  [ADDRESS_931558] be 
assigned in the IWRS.  
6.5 Randomisation criteria  
Not applicable for this trial.  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
VV-CLIN-281603 1.0 .
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
Status:  Final  
Page:  [ADDRESS_931559] print  the "code break confirmation" notification generated by [CONTACT_8784], record the 
reason and sign and date the document. Treatment with trial product can be resumed if there are no 
safety concerns at the discretion of the investigator.  
When the blind is broken , the treatment allocation will be accessible to the investigator and the 
Novo Nordisk Global Safety department. If IWRS is not accessible at the time of blind break, the 
IWRS helpdesk should be contact[INVESTIGATOR_530]. Contact [CONTACT_136758] I .  
7.5 Prepa ration/Handling/Storage/Accountability  
Only subjects enrolled in the trial may receive trial product and only authorised site staff may 
supply or administer trial product. Each t rial site will be supplied with sufficient trial products for 
the trial on an on -going basis controlled by [CONTACT_8784]. Trial product will be distributed to the trial 
sites according to screening and randomisation.  
The investigator must confirm that appropria te temperature conditions have been maintained during 
transit for all trial products received and any discrepancies are reported and resolved before use of 
the trial products.  
All trial products must be stored in a secure, controlled, and monitored (manual  or automated) area 
in accordance with the labelled storage conditions with access limited to the investigator and 
authorised site staff. For the storage and in -use conditions see the trial materials manual (TMM) and 
the labels of trial product. The invest igator must inform Novo Nordisk immediately if any trial 
product has been stored outside specified conditions. Additional details regarding handling of 
temperature deviations can be found in the TMM. Trial product that has been stored improperly 
must not b e dispensed to any subject before it has been evaluated and approved for further use by 
[CONTACT_3454].  
Subjects must return all used, partly used and unused trial products as instructed by [CONTACT_093]. 
The investigator is responsible for drug accountab ility and record maintenance (i.e. receipt, 
accountability and final disposition records). Drug accountability must be performed in the IWRS 
by [CONTACT_167803] -injectors as returned either as used/partly used, unused or as lost.  
Destruction of trial produc ts can be performed on an ongoing basis and will be done according to 
local procedures after accountability is finalised by [CONTACT_41138]. 
Destruction of trial products must be documented in the IWRS.  
All returned, expi[INVESTIGATOR_687280] (for technical complaint samples see Appendix 6 ) 
must be stored separately from non -allocated trial products. No temperature monitoring is required. 
Non-allocated trial products including expi[INVESTIGATOR_687281], 
at the latest at closure of the trial site.  
In case local restrictions due to epi[INVESTIGATOR_901]/pandemic lead to lockdown of a site , alternative ways of 
dispensing may be used if permitted by [CONTACT_427]  (see Appe ndix 9  for further details ). 
Japan: For country specific requirements, please see Appendix 8 . 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
Status:  Final  
Page:  [ADDRESS_931560] of the importance of following the instructions including taking 
the trial products as prescribed. Additionally, reporting of changes in the dose taken and monitoring 
of drug accountability will support documentation of treatment compliance . 
7.7 Concomitant medication  
Semaglutide/placebo will be added on top of standard -of-care treatment. Changes to standard -of-
care medications will be allowed during trial conduct  to optimise recommended standard -of-care. 
Initiatin g GLP -[ADDRESS_931561].   
At screening  subjects are required to be treated with a stable  maxim um labelled or  tolerated dose of 
a RAAS blocking agent (an ACE inhibitor or an ARB) as standard -of-care treatment for CKD in 
T2D. The maxim um labelled  dose will be assessed by [CONTACT_687297].  If the subject is not treated with a RAAS blocking agent, previous treatment 
attempt must be documented in medical r ecords and that this has led to intolerance or unacceptable 
side effects. If intolerance for an ACE -inhibitor is documented, due to cough , a treatment attempt 
with an ARB must have been made. If a subject is treated with the maximum tolerated dose but not 
the maximum labelled dose of the RAAS blocking agent a previous dose escalation attempt is not a 
requirement , but the reason why the subject is not expected to tolerate a higher dose must be 
documented in the medical records.  
Anti-hyperglycaemic  and CKD st andard -of-care treatment is considered background treatment and 
will not be provided by [CONTACT_3454] A/S.  
For randomised subjects t he following medication(s) other than the trial product that the subject is 
receiving at the time of screening (V1) or receiv es during the trial must be recorded in the electronic 
case report form ( eCRF ): 
•medication to treat T2D
•medication to treat CKD
•medication to treat or prevent CV disease
•medication administered in relation to AEs listed in Section 9.3
•medication administered  in relation to a clinical trial for COVID -19 prevention or treatment
•an approved COVID -[ADDRESS_931562] be recorded in the eCRF along  with start date and stop date or continuation 
and related AE number when applicable. For anti -hyperglycaemic  medication and for RAAS 
blocking agents (ACE inhibitors and ARBs), the total daily dose needs to be included in the e CRF. 
Stable dose changes (2 weeks or more) should be captured as a new concomitant medication with 
the new dose and relevant start and stop date.  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
Status:  Final  
Page:  [ADDRESS_931563] be recorded at each vis it. If a change is due to an AE or 
serious adver se event (SAE) , then this must be reported according to Section 9.3.  
7.[ADDRESS_931564] s and interference with safety 
data collection, initiating GLP -1 receptor agonists  should be avoided between the end  of treatment 
visit and the follow -up visit. All other medications are allowed.  
Brazil: For country specific requirements, please see Appendix 8 . 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  30 of 88 
 
8 Discontinuation/Withdrawal criteria   
8.[ADDRESS_931565], if the following applies:  
1. Pregnancy  
2. Intention of becoming pregnant  
3. Simultaneous participation in another clinical trial of an approved or non -approved 
investigational medicinal product * 
4. If acute pancreatitis is suspected, trial product must be discontinued; and if confirmed, trial 
product must not be restarted  
5. Treatment with another GLP -[ADDRESS_931566]  
6. Other safety concerns  
*Simultaneous participation in a trial with the primary objective of evaluating an approved or non -
approved investigational medicinal product for prevention or treatment of COVID -[ADDRESS_931567].   
Ad 3: With the exception of an approved or non -approved investigational product for prevention or 
treatment of COVID -19, subjects must not receive an investigational product from another clinical 
trial. If done, treatment with trial product must be discontinued. If the use of investigational medical 
product in the other trial is discontinued, treatment with trial product can be resumed if there are no 
safety concerns at the discretion of the investigator . 
For subjects who are discontinued for any reason, a Novo Nordisk medical expert [INVESTIGATOR_687327], whether the discontinuation will be 
permanent or temporary (see Section 8.1.1 ). For some events , when the circumstances have 
changed and/or there are no longer safety concerns, treatment with trial product may be continued 
or resumed at the discreti on of the investigator and in agreement with the Novo Nordisk medical 
expert. If a subject becomes pregnant during the trial, the trial product must be discontinued 
immediately and must not be re -initiated until breast feeding, if performed, has stopped. I f a subject 
intends to become pregnant, the trial product must be discontinued at least 5 weeks  prior to the 
planned intention  (Appendix 5 ). 
If a trial product is discontinued, the subject should continue to follow the trial schedule without 
being withdrawn from the trial and encouraged to attend the site for at least the end of treatment and 
follow -up visit s in order to collect the required data for the analysis of the primary (and 
confirmatory secondary) endpoints. Subjects must be educated about the continued scientific 
importance of their data, even if they discontinue trial p roduct.  The primary reason for 
discontinuation of trial product must be specified in the eCRF, and final drug accountability must be 
performed.  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  31 of 88 
 
The long half -life of semaglutide (approximately one week) should be considered when initiating 
new anti -hypergl ycaemic  treatment after discontinuation of the trial product.  
8.1.[ADDRESS_931568] may withdraw consent at any tim e at his/her own request. Only subjects who withdraw 
consent will be considered as withdrawn from the trial.  
If a randomised subject is considering withdrawing from the trial, the investigator may offer the 
subject flexible participation in the trial . This could be attending fewer visits (i.e. reduced visit 
schedule), converting site visits to phone contacts, treatment pause, or only being followed -up for 
AEs, especially those related to the primary objective. It must be explained to the subject that this 
must include information on their AEs, especially those related to the primary objective that 
occurred since last contact [CONTACT_504429]. This is important to ensure that the information gained is 
complete and accurate, and that the correct conclusions are  drawn. Only if the subject declines all 
alternatives, should the subject be recorded as withdrawn.  
Although a subject is not obliged to give his/her reason(s) for withdrawing, the investigator must 
make a reasonable effort to ascertain the reason(s), whil e fully respecting the subject's rights. Where 
the reasons are obtained, the primary reason for withdrawal must be specified in the end of trial 
form in the eCRF.  
Final drug accountability must be performed even if the subject is not able to come to the tr ial site.  
If a subject withdraws from the trial, he/she may request destruction of any samples taken and not 
tested, and the investigator must document this in the medical record. If  the subject withdraws 
consent, Novo Nordisk may retain and continue to u se any data collected before such a withdrawal 
of consent.  
Mexico: For country specific requirements, please see Appendix [ADDRESS_931569] fails to return to the trial site for a required visit:  
• The site must attempt to contact [CONTACT_687298] a nd/or should continue in the trial.  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  32 of 88 
 
• Before a subject is deemed lost to follow -up, the investigator must make every effort to contact 
[CONTACT_423] , see Section 5.2. The following contact [CONTACT_687299]’s source documents where as a minimum, renal impairment  status related to primary 
objective, the AE status and/or vital status (dead or alive) should be  determined:  
• To subjects: three phone calls and one written contact (e.g. certified letter)  
• To the primary physician and/or other health care professionals: phone calls until 
contact [CONTACT_204278]  
• If direct contact [CONTACT_687300], relatives or other per son(s) will be 
contact[INVESTIGATOR_530]: three phone calls and one written contact  
• Search/contact [CONTACT_687301], if available and allowed by 
[CONTACT_687302] , he/she will be considered to 
have withdrawn from the trial with a primary reason of lost to follow -up. A subject cannot be 
declared lost to follow -up before the trial has come to an end.  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  33 of 88 
 
9 Trial assessments and procedures   
• Trial procedures and their timing are summarised in the flowchart (Section 1). 
• Informed consent must be obtained before any  trial related activity, see Appendix 3 . 
• All screening evaluations must be completed and reviewed to confirm that potential subjects 
meet all eligibility criteria.  
• The investigator will maintain a screening log to record details of all subjects screened and to 
confirm eligibility or record reason for screen failure, as applicable.  
• At screening, subjects will be provided with a card stating that they are participating in a trial 
and giving contact [CONTACT_41142].  
• Adherence to the trial design requirements, including those specified in the flowchart, is 
essential and required for trial conduct.  
• The investigator should inform the subjects’ primary physician, if applicable, about the subjects’ 
participation in the trial if the subject agrees to the primary physician being informed.  
• Each subject should be asked to provide contact [CONTACT_508091] (preferably at least 3), 
e.g. relatives, primary care provider or other, to whom the investigator can contact [CONTACT_687303].  
• The investigator must ensure to keep regular contact [CONTACT_444980], a nd at all times have updated contact [CONTACT_687304]. Even if a visit (or phone 
contact) is missed and it is not possible to re -schedule, the investigator must take every effort to 
have all subjects followed for primary endpoint events (see Sec tion 4.2.1 ).  
• All of the assessments and procedures at a given trial visit do not need to be performed on the 
same day, provided that they are compl eted within the visit window.  
• Review of completed PROs, laboratory reports, etc. must be documented either on the 
documents or in the subject's source documents.  The review must be performed by [CONTACT_98225] . 
• Repeat samples may be taken for technical iss ues and unscheduled samples or assessments may 
be taken for safety reasons or to confirm the primary endpoint (see Section 9.2.2 ). Please refer 
to Appendix 2  for further details on laboratory samples.  
• There are no fasting visits.  
• In case local restrictions due to epi[INVESTIGATOR_901]/pandemic lead to lockd own of a site, site visits can be 
performed as home nursing (see Appendix 9 ) 
9.1 Optional pre -screening   
The i nvestigator may, after obtaining separate informed consent, perform pre -screening of potential 
trial candidates. It is not necessary to obtain full informed consent for the remaining trial period 
before pre -screening. Pre-screening assessments include obtaining blood and urine samples for 
eGFR and/or UACR and/or HbA 1c. The subject must hav e been/be in usual health condition at the 
time of sample collection used for inclusion as evaluated by [CONTACT_687296] a 
RAAS blocking agent, according to inclusion criterion 6  (see Section 6.1). The pre -screening 
samples must be analysed locally  with standardised assays as described in Appendix 2 . The 
parameters  that fulfil inclusion criteria  can be used to determine eligibility for the trial , if 
measurements were taken no more than 90 days  prior to screening and are doc umented in the  
medical records . Those subjects  determined eligible for the trial based on these results will follow 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  34 of 88 
 
the flowchart schedule for all screening assessments including eGFR, UACR and HbA 1c (see 
Section 1) to determine the baseline values (see Section  10.3). 
Results of pre -screening assessments will not be collected in the trial database and will not be 
monitored  unless used to fulfil inclusion criteria (see Section 6.1). Conce rns related to any pre -
screening assessment must not be reported as an AE. 
Pre-screening assessments performed after signature [CONTACT_687330] [CONTACT_3454] A/S.  
China: For country specific requirements, please see Appendix 8 . 
[LOCATION_013]: For country specific requirements, please see Appendix 8 . 
9.2 Efficacy assessments   
Planned time points for all efficacy assessments are provided in the flowchart (Section 1). 
9.2.[ADDRESS_931570] of when the self -measured 
plasma glucose values should be measured and how to note the values and dates. The measurements 
are supportive for  the investigator’s treatment decisions when optimising glycaemic control . 
The BG meters  provided by [CONTACT_3454] , use test strips calibrated to plasma values. Therefore, all 
measurements performed with capi[INVESTIGATOR_687282], which will be shown on the display.  
9.2.[ADDRESS_931571] be conducted in 
accordance with the flowchart and the laboratory manual.  
Collection of creatinine values from medical records  
Throughout the trial period the investigator should report  (in the eCRF) any creatinine values 
measured at a local laboratory and  documented in medical records if they are considered to reflect 
the usual kidney function. Values that are considered to be due to reversible cause (e.g. acute 
hospi[INVESTIGATOR_11956], volume depletion or nephrotoxic medication) should not be reported.  
If a subje ct initiates chronic dialysis or receives a renal transplant, further collection of creatinine 
values from medical records is not needed.  
Central laboratory co nfirmatory eGFR samples  
When an eGFR  result  from the central laboratory  indicates that one of th e thresholds has been 
reached  (see Section 4.2.1 ),  
• ≥ 50% reduction in eGFR  from baseline  or 
• eGFR < 15 mL/min/1.73 m2 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  [ADDRESS_931572] central laboratory 
measurement.  
Confirmatory tests should not be collected after the end of treatment visit.  
9.2.3 Patient reported outcomes   
The EQ -5D-5L questionnaire is a patient reported outcome (PRO) tool. The PRO will be used to 
estimate the impact on subjects’ health -related quality of life and provides a description of subjects’ 
problems by [CONTACT_55686] s (descriptive system), a score for overall self -rated health (visual analogue 
scale [VAS] as well as an index score [EQ -5D-5L index]). If clarification of the test is needed, care 
must be taken not to bias the subject. Data from completed questionnaires m ust be transcribed to the 
eCRF by [CONTACT_687305].  
9.3 Adverse events   
The definitions of AEs and SAEs can be found in Appendix 4 . 
Japan: For country specific req uirements, please see Appendix 8 .  
The investigato r is responsible for detecting, documenting, recording and following up on:  
• All SAEs  
• AEs leading to discontinuation of trial product  
• AEs related to COVID -19, irrespective of seriousness.  
Note: Suspected COVID -[ADDRESS_931573] (antigen or antibody) should be reported, if available.  
• Selected types of AEs (SAEs and non -SAEs) requiring additional data collection (on specific 
event forms) and events for adjudication (see Table  9-1). 
9.3.1 Time period and frequency for collecting AE and SAE information   
All events meeting the definition of an SAE (see  Appendix 4 ) and events listed in Section 9.[ADDRESS_931574] be collected and reported. This includes events from the day of rando misation until 
the follow -up visit/end of trial visit, at the time points specified in the flowchart  (Section 1). All 
SAEs will be recorded and reported to Novo Nordisk or designee within [ADDRESS_931575] has been 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  36 of 88 
 
discontinued from/completed the trial, and the investigator considers the event to be 
possibly/probably related to the investigational trial product or trial participation, the investi gator 
must promptly notify Novo Nordisk.  
The method of recording, evaluating and assessing causality of AE and SAE and the procedures for 
completing and transmitting SAE reports are provided in Appendix 4 . Timelines for reporting of 
AEs, including events for adjudication, Section [IP_ADDRESS] , are listed in Figure  9-1. 
Some AEs require additional data collection via a specific ev ent form. The relevant specific events 
are listed in Table  9-1 and the reporting timelines in.  
Figure  9-1 Decision tree for determining the event type and the respective forms to 
complete with associated t imelines   
 
 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  38 of 88 
 
[IP_ADDRESS]  Events for adjudic ation   
The list of events for adjudication can be found in  Table  9-1and the reporting timelines in 
Figure  9-1.  
Event adjudication will be performed for event s in randomised subjects. These events are reviewed 
by [CONTACT_687306] (EAC) in a blinded manner; refer to 
Appendix 3  for further details.  
There are four ways to identify events relevant for adjudication as described below:  
1. Investigator -reported events for adjudication: When reporting AEs, the investigator must select 
the appropriate AE category based on pre-defined criteria (see  Table  9-1).If the selected AE 
category is in scope for adjudication, an event specific adjudication form must be completed. 
Relevant predefined source documents must, if obtainable, be collected and uploaded to the 
Event Adjudication System (EAS).  
2. Deaths (AEs reported with fatal outcome): When an AE is reported with fatal outcome, a death 
adjudication form will appear in the eCRF . This form must be completed and all source 
documents associated with the subjects’ death must, if obtainable, be collected and uploaded to 
the EAS.  
3. AE search (standardised screening): All AEs not directly reported by [CONTACT_687307], will undergo screening to identify potential events for adjudication. If 
the AE is deemed relevant for adjudication, an event specific adjudication form will be 1. abdominal pain consistent with acute pancreatitis (acute 
onset of a persistent, severe, epi[INVESTIGATOR_687283])  
2. serum lipase activity (and/or amylase activity) at least 
three times greater than the upper limit of normal  
3. characteristic findings of acute pancreatitis on imaging  
 
Diabetic retinopathy  
New onset or worsening of diabetic retinopathy  Not applicable  Specific event form  
Malignant neoplasm  
Malignant neoplasm confirmed by [CONTACT_687308].  Not applicable  Specific event form  
Medication error  
Medication errors related to trial product. For details regarding 
medication errors, see Appendix [ADDRESS_931576] 
also be completed  
Japan: For country 
specific requirements, 
refer to Appendix 8 . 
 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  [ADDRESS_931577], if obtainable, be collected and uploaded to the EAS.  
4. EAC -identified events: During review of source documents provided for another event for 
adjudication, the EAC may identify additional events in scope for adjudication that were not 
initially reported by [CONTACT_093]. In these instances, the investigator will be notified of the 
newly identified event and has the option to report the EAC -identified event. Regardless of 
whether the investigator decides to report the event, it will undergo adj udication. Occasionally, 
EAC -identified events may require the investigator to collect additional source documents and 
upload these, if obtainable, to the EAS.  
The specific adjudication form for the event in question should be completed in the eCRF within 7 
calendar days of  the investigator's first knowledge of the event.  
Copi[INVESTIGATOR_687284], subject number, AE number (if 
applicable), redacted (anonymised of personal identifiers) and uploaded to the EAS as soon as 
possible and preferably within 4 weeks. If no or insufficient source documents are provided to the 
adjudication supplier, the investigator can be asked to complete a clinical narrative to be uploaded 
to the EAS.  
If new information becomes available for an eve nt sent for adjudication, it is the responsibility of 
the investigator to ensure the new information is uploaded to the EAS.  
An Event Adjudication site manual will be provided to each site detailing which  source documents 
are relevant and how these should be provided to the adjudication supplier. The anonymization and 
labelling requirements are also described in the site manual.  
The assessments made by [CONTACT_687309]  (CTR) . 
9.3.2 Method of detecting AEs and SAEs   
Care should be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and non -
leading verbal questioning of t he subject is the preferred method to inquire about events.  
9.3.3 Follow -up on AEs and SAEs   
After the initial AE/SAE report, the investigator is required to proactively follow each sub ject at 
subsequent visits/contacts. All events  will be followed until resolution, stabilization, or if the event 
is otherwise explained (e.g. chronic condition) or the subject is lost to follow -up (as defined in 
Section 8.3). Further information on follow -up procedures is given in Appendix [ADDRESS_931578] under clinica l investigation. Novo Nordisk 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  [ADDRESS_931579]/independent ethics committee ( IRB/IEC ), and 
investigators.  
To avoid introducing bia s and to maintain the integrity of the primary analysis, Novo Nordisk will 
exempt SAEs that are part of the primary objective evaluation from unblinding and reporting during 
trial conduct, even if the cases fulfil the definition of suspected unexpected ser ious adverse 
reactions (S[LOCATION_003]Rs). The DMC ( Appendix 3 ) receives unblinded data and makes recommendations 
to the Novo Nordisk safety committee on an ongoing basis. This ensures adequate monitoring of 
safety while maintaining SAE reports related t o the primary endpoint blinded for Novo Nordisk.  
At the end of the trial, when treatment is revealed, all exempted cases which meet the criteria for 
expedited reporting S[LOCATION_003]Rs will be submitted to the regulatory authorities. Because multiple cases 
will be identified simultaneously, Novo Nordisk will not be able to fulfil the [ADDRESS_931580] be prepared for  S[LOCATION_003]Rs according to local regulatory requirements 
and Novo Nordisk policy and forwarded to investigators as necessary.  
An investigator who receives an investigator safety report describing a n SAE or other specific 
safety information (e.g. summary or listing  of SAEs), from Novo Nordisk will review and then file 
it along with the investigator's brochure and will notify the IRB/IEC, if appropriate according to 
local requirements.  
9.3.5 Cardiovascular and death events   
Specified in  Table  9-1 
9.3.6 Disease -related events and/or disease -related outcomes not qualifying as an AE or 
SAE   
Not applicable for this trial. 
9.3.[ADDRESS_931581]  trial-related activity after 
obtaining informed conse nt and until pregnancy outcome.  
If a pregnancy is reported in female subjects, the investigator should inform Novo Nordisk within 
14 calendar days of learning of the pregnancy and should follow the procedures outlined in  
Figure  9-2 and Appendix 5 .  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  [ADDRESS_931582]'s medical r ecord. Abnormal pregnancy 
outcome (e.g. spontaneous abortion, foetal death, stillbirth, congenital anomalies and ectopic 
pregnancy) is considered an SAE.  
Figure  9-2 Decision tree for determining the forms to  complete with associated timelines 
for pregnancy   
Maternal form 1b  
≤ 14 calendar days after birthMaternal form 1a
≤ 14 calendar daysAfter birth/
termination 
of pregnancy
No additional 
action Normal outcome Maternal form 2 ≤ 14 calendar days
Paternal form*1 ≤ 14 calendar days Abnormal outcome 
Pregnancy 
verified
*1 Further information collected on Paternal form for male partners of 
female subjects requires signing of specific informed consent.
AE/SAEs in connection with the pregnancy and in the foetus/newborn 
should follow the timelines in Figure 2.Prior to 
birth or 
pregnancy 
termination For female subjects
 
9.3.8 Medical device incidents (including malfunctions)   
Not applicable for this trial. Refer to technical complaints in Section 9.3.[ADDRESS_931583] assess whether a technical complaint is related  to an AE.  
The definitions and reporting process for technical complaints can be found in Appendix 6. 
Timelines for reporting technical complaints are listed in Figure  9-3. 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  43 of 88 
 
The following concomitant illness/medical history should be reported in the eCRF:  
• T2D including date of diagnosis  
• Diabetes complications, incl uding hypoglycaemia unawareness  and neuropathy  
• History of kidney disease including data on previous eGFR and UACR measurements  
• History of CV disease  including peripheral artery disease  
• History of eye diseases  
• History of pancreatitis  
• History of gallbladder  diseases  
• History of malignant neoplasms  
• Other relevant concomitant illness/medical history  including  COVID -[ADDRESS_931584] the finding on 
the Medical History/Concomitant Illness form if it is present at randomisation. Any new finding 
fulfilling the SAE definition (see Appendix 4 ) or included in Section 9.3 or Table  9-1 during the 
trial and any clinically significant worsening from baseline (visit 2) must be reported as an AE (see 
Section 9.3). 
9.5.1 Physical examinations   
A physical examination will include assessments of the:  
• General appearance  
• Thyroid gland  
• Respi[INVESTIGATOR_2133]  
• Cardiovascular system  
• Abdomen  
• Extremities  
• Skin 
• Central and peripheral nervous system  
Relevant findings present at or prior to randomisation should be recorded on the Medical 
History/Concomitant Illness form in the eCRF in accordance with Section  9.5. Findings not present 
at randomisation should be reported as AEs according to Section  9.3.  
Body measurements (height and weight) will also be measured and recorded as specified in the 
flowchart  (Section 1). Height should be assessed without shoes. Body weight should be assessed in 
light clothes without shoes.  
Investigators should pay special attention to clinical signs related to previous serious illnesses.  
9.5.2 Vital signs   
• Blood pressure and pulse measurements should be preceded by [CONTACT_2669] [ADDRESS_931585] in a sitting position and a quiet setting wi thout distractions (e.g. television, cell phones).  
• Blood pressure will consist of [ADDRESS_931586] be entered in the eCRF and the 
average of the 3 b lood pressure readings will be calculated in the eCRF.  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  44 of 88 
 
• Blood pressure and pulse measurements will be assessed with a completely automated device. 
Manual techniques will be used only if an automated device is not available.  
• The measured values should be rec orded without rounding.  
9.5.[ADDRESS_931587] or  another suitably  qualified health 
care provider (e.g . optometrist) must be available and evaluated by [CONTACT_111419]. The eye examination should be performed as a fundus 
photography (e.g. 2 -field 60 degree or better, colour or red -free) or by [CONTACT_41157] -lamp biomicrosc opy 
examination (e.g. using a precorneal or corneal contact [CONTACT_41158]) . Pharmacological pupil -
dilation is a requirement unless using a digital fundus photography camera specified for non -dilated 
examination.  
If the subject had such an eye examinatio n performed within 90 days prior to screening, the 
investigator may base his/her  evaluation upon the results of that examination . The examination must 
be repeated before randomisation if the subject has experienced worsening of visual function since 
the last examination.  If the applicable eye examination was performed before the subject signed the 
informed consent form, it must be documented that the reason for performing the examination was 
not related to this trial.  
After randomisation an e ye examinati on performed according to the above must be performed as 
per the flowchart within visit window (see Section 1) or within [ADDRESS_931588] be recorded as concomitant illness/medical  history, while relevant findings 
occurring after randomisation should be reported as an AE, i f applicable according to Section 9.3. 
The subject must be informed that pharmacologically pupil -dilated fundus examination may make 
the eyes more sensitive to light and cause blurry vision, and that driving should not take place  if the 
vision is impaired.  
India: For country specific requirements, please see Appendix [ADDRESS_931589] be conducted in 
accordance with the laboratory manual and the flowchart in Section 1. 
9.6 Pharmacokinetics   
Not applicable for this trial.  
9.7 Pharmacodynamics   
Not applicable for this trial.  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  [ADDRESS_931590] become 
available. The analyses may include biomarkers currently known or discovered in the future.  
Analyses of circulating biomarkers may include analysis of  hormones, metabolites or other non -
genetic plasma or serum parameters  with the purpose of understanding a nd predicting response to 
semaglutide as well as to increase understanding nephrologic and cardiometabolic diseases.  
These samples need to be frozen and should be sent in batches to the central laboratory. The 
analyses are likely to be performed after the trial has come to an end, and results will therefore not 
be part of the CTR. The biobank samples may be stored up to 15 years after end of trial at a central 
laboratory (see Appendix 7 ). 
Brazil , China,  Israel , South Africa  and Turkey : For country specific requirements, please see 
Appendix 8 . 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  46 of 88 
 
10 Statistical considerations   
10.1 Sample size determination   
The trial is designed with 90% power to confirm superiority for the primary endpoint, i.e., reject the 
null-hypothesis H 0: HR >=1.[ADDRESS_931591] the one -sided alternative H a: HR <1.[ADDRESS_931592] ratio comparing semaglutide to placebo. For the group sequential design, a n alpha 
spending function will be used that approximates O'Brian Fleming stoppi[INVESTIGATOR_687285] I error probability of 2.5% (one -sided).  Based on a randomisation ratio of 1:1 and a 
true HR of 0.8 , a total of 8 54 primary endpoint event s are required for 90% power . 
The assumptions for all the power calculations below are based on analysis of data from the 
subpopulation, approximately 5%, from the liraglutide CV outcome trial EX2211 -3748 (LEADER), 
which fulfilled inclusion criteria 2-6 described in Section 6.1. All assumptions are further supported 
by [CONTACT_687310]9535 -3744 (SUSTAIN 6).  
For the calculation of number o f randomised subjects it is assumed that:  
• annual primary endpoint rate in the placebo group is 7.5% 
• uniform recruitment occurs in 21 months  
• annual lost to follow -up rate in both treatment groups is of 1% 
• trial duration is five years and five weeks (from fi rst subject randomised to last subject last visit 
(LSLV )) 
Under these assumptions a total of 3, [ADDRESS_931593] of this trial. The event rate observed in LEADER for this 
nephropathy composite outcome was 9.4% in the placebo group. Recently conducted trials with 
SGLT -[ADDRESS_931594] on new or wor sening nephropathy.17, 18 Taking 
this into account, a primary end point event rate of 7.5% in the placebo group and hazard ratio of 0.8 
is assumed.  
The annual loss rate of 2%  (considered a worst case scenario) is based on lost to follow -up rates 
seen in the SUSTAIN 6  and LEADER trials, while also taking into account missing data for eGFR 
due to e.g. missing blood samples among subjects being followed.  
Confirmatory secondary endpoints  
If superiority is confirmed for the primary endpoint the below confirmatory secondary endpoints 
will be controlled for multiplicity through a hierarchical testing strategy.  The marginal powers 
below are calculated under the assumptions that the trial continues to the final analysis  and that 
testing is done at a 2.5% level (one -sided).     
The confirmatory se condary endpoint, annual rate of change in eGFR, is analysed using a linear 
random regression  model . Under the assumption of a difference in slope of 1mL/min/1.[ADDRESS_931595] variance for the slope of 20 and a residual 
variance of 45, the marginal power is >99%.  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  [ADDRESS_931596] ratio of 0.8, an annual loss rate of 1% and an annual event rate of 7% in the 
placebo group for the confirmatory secondary MACE endpoint, the marginal power for confirming 
superiority is 89%. With similar  assumptions for hazard ratio and loss rate and assuming an event 
rate of 5% in the placebo group, the marginal power for the third confirmatory secondary endpoint, 
time to all -cause death, is 7 8%.  
10.2 Definition of analysis sets   
The full analysis set (FAS) is defined as all randomised subjects  and grouped in analyses according 
to the treatment assigned at randomisation.  
Subjects  continue in the trial an d are part of FAS regardless of discontinuation of randomised 
treatment and any other intercurrent event. A subject  is considered lost to follow -up if the subject  
does not complete the trial and does not withdraw consent. Trial completers are defined as subject s 
that either attend the follow -up visit or who die during the in -trial period.  
The in -trial observation period for a subject  is defined as the period from date of randomisation to 
the first of (both inclusive):  
• date of follow -up visit  
• date when subject  withdrew consent  
• date of last contact [CONTACT_59299]  (for subject  lost to follow -up)  
• date of death  
In line with the estimand for this trial, all endpoints will be evaluated in terms of the in -trial 
observation period only . 
10.3 Statistical analyses   
A comprehensive statistical analysis plan (SAP) will be available before firs t subject  first visit , 
including details of interim testing.  
Novo Nordisk will perform the statistical analyses except the int erim testing, see Section  10.3.[ADDRESS_931597], DMC analyses, interim testing, and external to Novo 
Nordisk will repeat the statistical analyses of the primary endpoint and secondary confirmat ory 
endpoints.  
General considerations  
For confirmatory endpoints controlled  for multiplicity, estimated treatment effects will be presented 
together with two -sided 95% confidence intervals (CIs) and one -sided p -values for tes ts of the  
hypotheses  of superiority . For reporting  of results, the estimated treatment effect and the 95% 
confidence interval will be accompanied by [CONTACT_112913] -sided p -value.  
For non -confirm atory endpoints, the estimated treatment effects will be presented together with 
two-sided 95% confidence intervals and two -sided p -values corresponding to testing the exploratory 
hypotheses of no difference.  
Unless otherwise mentioned, baseline assessment  is defined as the latest available measurement 
from the randomisation visit (V2) or the screening visit (V1). Thus, if a V2 assessment is missing 
then the assessment from V1 will be used as the baseline assessment, if available. For eGFR, the 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  48 of 88 
 
baseline ass essment is defined as the mean of the two assessments from the randomisation visit 
(V2) and the screening visit (V1). If only one of the assessments is available, this will be used as the 
baseline assessment. For UACR, the baseline assessme nt is defined as the mean of the two 
assessments  from the randomisation visit (V2). If only one of the assessments  is available, this will 
be used as the baseline assessment.  
Missing data are defined as data that are planned and can be observed but are not  present in the 
database. This implies that data that are structurally missing due to death or administrative 
censoring are not considered missing.  
If adjudicated , time-to-event endpoints are defined based on outcomes of the EAC evaluations. If a 
subject e xperience the event of interest during the in -trial observation period, the endpoint is the 
time from randomisation to the date of event. While vital status is ascertained systematically 
throughout the trial, non -fatal events cannot be systematically colle cted after withdrawal of consent, 
lost-to-follow -up, or after end -of-trial follow -up visit. For this reason, any event occurring after the 
in-trial observation period is not included in analyses, unless otherwise stated.  
Time -to-event endpoints are censore d at the end of the in -trial period if the event of interest did not 
happen during this period and the subject  is alive at the end of the period. Censoring due to lost to 
follow -up and withdrawal of consent assume independent censoring. Additional anticipa ted 
intercurrent events and handling of these in context of the estimand for the primary and 
confirmatory secondary time -to-event endpoints are described in Table  10-1. 
10.3.[ADDRESS_931598] ratio for comparing semaglutide versus p lacebo will be estimated from a  stratified Cox 
proportional hazards model with treatment (semaglutide, placebo) as fixed factor together with the 
2-sided 95% confidence interval and one -sided p -value for hypothesis testing. Stratification is by 
[CONTACT_687311] -2 inhibitors (yes/no) at baseline. The score test from the Cox model will be used for 
testing. The following superiority hypothesis will be tested:  
H0: HR ≥ 1.[ADDRESS_931599] H a: HR < 1.0.  
Superiority of semaglutide versus placebo will be considered confirmed if the associated H 0 is 
rejected based on no minal significance level derived from the pre -specified alpha spending based 
on the actual observed number of events available for the analysis. Final inference on termination is 
adjusted for the group sequential design by [CONTACT_687312] p -value and 
95% CI and HR.  
In the primary analysis missing data for scheduled central laboratory eGFR values due to e.g. 
missing blood samples while subjects are still being followed are not imputed, implicitly assuming 
no eGFR component events  observed during the in -trial observation period with missing eGFR 
values.  
Sensitivity analysis  
If superiority is established for the primary endpoint, the following sensitivity analysis is 
performed. The primary analysis assumes independent censoring for subjects who are lost to 
follow -up or who withdrawn consent. To investigate the impact of this assumption on the 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  [ADDRESS_931600] their event times imputed with an 
increasing penalty in the sense that their risk of a primary endpoint event is increased (the penalty) 
following censoring compared to while under observation. The placebo subjects will be imputed 
with no p enalty, i.e. assuming same event rate before and after censoring. Multiple imputed data 
sets will be analysed with separate stratified Cox regressions as for the primary analysis and results 
will be combined using Rubin’s rule. The tippi[INVESTIGATOR_687286].  
10.3.2  Secondary endpoints   
Secondary endpoints are categorised as being confirmatory when they are analy sed under 
multiplicity control . 
[IP_ADDRESS]  Confirmatory secondary endpoints   
If superiority is established for the primary endpoint, t he superiority hypothesis stated in Section  
10.3.1  is tested for the three confirmatory secondary endpoints under multiplicity control via a 
hierarchical testing scheme  using the following order:  
1. Annual rate of change in eGFR ( total eGFR slope)  
2. Time to first occurrence of MACE  
3. Time to occurrence of all -cause death  
The testing procedure is stopped the first time an analysis fails to confirm superiority of the 
endpoint in question . The statistical significance l evels of the confirmatory secondary endpoint 
analyses are specified in the SAP.   
The annual rate (slope) of decline in eGFR will be compared between treatment groups based on a 
linear random regression model on eGFR values with treatment,  use of SGLT -2 inh ibitors (yes/no) 
at baseline,   time (as a continuous variable) and treatment time interaction as fixed effects, and 
including subject effect as a random intercept and time as a random slope. The random intercept 
and slope is assumed to be bivariate normal distributed with mean zero and an unstructured 
covariance matrix. The independent error term is assumed to be identical univariate normal 
distributed with mean zero. To estimate the slope the model will be fitted to  scheduled central 
laboratory baseline and post-baseline data . The parameter of interest is the coefficient for the 
treatment and time interaction term, which measures the slope difference between semaglutide and 
placebo . The two confirmatory secondary time -to-event endpoints will be a nalysed  using the 
stratified Cox proportional hazards model as described for the primary endpoint.  
The following Table  10-1 describes in how  anticipate d intercurrent events during the trial are 
handled for confirmatory endpoints.  
 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  [ADDRESS_931601] and external to Novo Nordisk to prepare data for the DMC. The sequential ana lyses 
performed by [CONTACT_687313] (see Section  10.3.4 ) and safety data 
and will be performed to make recommendations regarding the ongoing conduct of the trial to 
ensure acceptable benefit/risk ratio for subjects  in the trial . 
10.4 Pharmacokinetic an d/or pharmacodynamic modelling   
Not applicable for this trial.  
 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  52 of 88 
 
11 Refer ences   
1. The European Parliament and the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Council of [ADDRESS_931602] of clinical trials on medicinal 
products for human use. 2001.  
2. Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, et al. Kidney 
disease and increas ed mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302 -
8. 
3. [LOCATION_006] Prospective Diabetes Study ([LOCATION_006]PDS) Group. Intensive blood -glucose control with 
sulphonylureas or insulin compared with conventional treatment and risk of complications 
in patie nts with type 2 diabetes ([LOCATION_006]PDS 33). Lancet. 1998;352(9131):837 -53, Erratum 
1999; 354: 602.  
4. Coca SG, Ismail -Beigi F, Haq N, Krumholz HM, Parikh CR. Role of intensive glucose 
control in development of renal end points in type 2 diabetes mellitus: systema tic review and 
meta -analysis intensive glucose control in type 2 diabetes. Arch Intern Med. 
2012;172(10):761 -9. 
5. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 
2012 Update. Am J Kidney Dis. 2012;60(5):850 -86. 
6. Sanof i-Aventis.  AVAPRO (irbesartan),   US Prescribing Information (PI). February 2016.  
7. Merch and CO. COZAAR (losartan), US Prescribing Information (PI). Mar 2013.  
8. Par Phrmaceutical. CAPOTEN (captopril), US Prescribing Information (PI). Dec 2014.  
9. Lewis  EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective 
effect of the angiotensin -receptor antagonist irbesartan in patients with nephropathy due to 
type 2 diabetes. N Engl J Med. 2001;345(12):851 -60. 
10. Brenner BM, Cooper ME, de Ze euw D, Keane WF, Mitch WE, Parving HH, et al. Effects of 
losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and 
nephropathy. N Engl J Med. 2001;345(12):[ADDRESS_931603] of angioten sin-converting -enzyme 
inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 
1993;329(20):1456 -62. 
12. Mann JFE, Ørsted DD, Brown -Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al. 
Liraglutide and Renal Outcomes in Type 2 Diabe tes. N Engl J Med. 2017;377(9):839 -48. 
13. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and 
Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:[ADDRESS_931604] 
of liraglutide on renal function: A randomized clinical trial. Diabetes Obes Metab. 
2017;19(2):239 -47. 
15. Bethel M, Mentz R, Merrill P, Buse J, Chan J, Goodman S, et al. Renal Outcomes in the 
EXenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes. 2018;67(Suppl. 
1). 
16. Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, et al. 
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate -to-severe 
chronic kidney disease (AWARD -7): a multicentre, open -label, randomised trial. Lancet 
Diabetes Endocrinol. 2018;6(8):605 -17. 
17. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin 
and Cardiovascular and Renal Event s in Type 2 Diabetes. N Engl J Med. 2017;377(7):644 -
57. 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  53 of 88 
 
18. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. 
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 
2016;375(4):323 -34. 
19. Tuttle KR , Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein -Fuchs J, et al. Diabetic 
kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 
2014;37(10):[ADDRESS_931605] to investigate the effects of Jardiance in adults with chronic kidney disease 2018 
[cited 2018 31 -May-2018].  
21. Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. 
Lower estimated GFR and higher alb uminuria are associated with adverse kidney outcomes. 
A collaborative meta -analysis of general and high -risk population cohorts. Kidney Int. 
2011;80(1):93 -104. 
22. Group IHS. Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be 
Reported in C linical Trials: A Joint Position Statement of the American Diabetes 
Association and the European Association for the Study of Diabetes. Diabetes Care. 
2017;40(1):155 -7. 
23. American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in 
Diabetes -2018. Diabetes Care. 2018;41(Suppl 1):S55 -S64. 
24. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO [ADDRESS_931606]. 2013;3(1):[ADDRESS_931607] amended by [CONTACT_941] 64th WMA General Assembly, 
Fortaleza, Brazil. October 2013.  
26. ICH Harmonised Tripartite Guideline. Guide line for Good Clinical Practice E6(R2),  Step [ADDRESS_931608], 
Reporting, Editing and Publication of Scholarly Work in Medical Journals; current version 
available at www.icmje.org . 
28. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoe y J, Horton R, et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. N 
Engl J Med. 2004;351(12):[ADDRESS_931609] of 2007 as amended by [CONTACT_43679] "Clinical 
Trials Registration and Results Information Submission". 21 September 2016.  
30. The European Parliament and the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Council of [ADDRESS_931610] of clinical trials on medicinal 
products for human use, article 11. Official Journal of the European Communities. 01 May 
2001.  
31. The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of the Council of 31 March 2004 laying dow n 
Community procedures for the authorisation and supervision of medicinal products for 
human and veterinary use and establishing a European Medicines Agency, article 57. 30 
April 2004.  
 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  54 of 88 
 
12 Appendices   
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  [ADDRESS_931611] visit  
MACE  major adverse cardiovascular event  
MALE  major adverse limb event  
PCD  primary completion date 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  [ADDRESS_931612]  upper limit of normal  
WOCBP  woman of childbearing potential  
 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
VV-CLIN-281603 1.0 .
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  59 of 88 
 
Appendix 3  Trial governance considerations   
1) Regulatory and ethical considerations  
• This trial will be conducted in accordance with the protocol and with the following:  
• Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki25 and applicable ICH Good Clinical Practice (GCP) 
Guideline26. 
• Applicable laws and regulations  
• The protocol, informed consent form, investigator’s brochure (as applicable) and other relevant 
documents (e.g. advertisements ), must be submitted to an IRB/IEC and reviewed and approved 
by [CONTACT_1201]/IEC before the trial is initiated.  
• Regulatory authorities will receive the clinical trial application, protocol amendments, reports 
on SAEs, and the CTR according to national requireme nts. 
• Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the trial design, except for changes necessary to eliminate an immediate safety 
hazard to trial subjects.  
• Before a trial site is allowed to start scr eening subjects, written notification from Novo Nordisk 
must be received.  
• The investigator will be responsible for:  
• providing written summaries of the status of the trial annually or more frequently in 
accordance with the requirements, policies, and proced ures established by [CONTACT_5040]/IEC and/or regulatory authorities  
• notifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures  
• providing oversight of the conduct of the trial at the site and adherence to 
requirements of ICH guidelines, the IRB/IEC, and all other applicable local 
regulations  
• ensuring submission of the CTR synopsis to the IRB/IEC.  
Japan , Mexico and Russia : For country specific requirements, please see  Appendix 8 . 
2) Financial disclosure  
Investigators and sub -investigators will provide Novo Nordisk with sufficient, accurate financial 
information as requested to allow Novo Nordisk to submit complete an d accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the trial and one 
year after completion of the trial.  
For US trial sites: verification under disclosures per Code of Federal Regulations (CFR) of 
Financial Conflict of Interest.  
3) Informed consent process  
• The investigator or his/her representative will explain the nature of the trial to the subject and 
answ er all questions regarding the trial. This includes the use of an impartial witness where 
required according to local requirements.  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  60 of 88 
 
• The investigator must ensure the subject ample time to come to a decision whether or not to 
participate in the trial.  
• Subjects must be informed that their participation is voluntary.  
• Subjects will be required to sign and date a statement of informed consent that meets the 
requirements of local regulations, ICH guidelines26, Declaration of Helsinki25 and the IRB/IEC 
or trial site.  
• The medical record must include a statement that written informed consent was obtained before 
any trial related activity and the date when the written consent was obtained. The authorised 
person obtaining the informed consent must also sign and date the informed consent form  before 
any trial related activity.  
• The responsibility of seeking informed consent must remain with the investigator, but the 
investigator may delegate the task of informing to a medically qualified person, in accordance 
with local requirements.  
• Subjects m ust be re -consented to the most current version of the informed consent form(s) 
during their participation in the trial.  
• The informed consent form will contain a separate form that addresses long -term storage of 
human samples and the use of samples for opt ional exploratory research. The investigator must 
explain to each subject the objectives of the exploratory research. Subjects must be told that 
they are free to refuse to participate and may withdraw their consent at any time and for any 
reason during the  storage period.  
• A separate informed consent form for optional pre -screening is available. This must be signed 
before any optional pre -screening activities are performed,  but it is not necessary to obtain full 
informed consent for the remaining trial perio d before pre -screening,  see Section 9.1. 
• A copy of the informed consent form(s) must be provided to the subject.  Brazil: For country 
specific requirements, please see Appendix 8 . 
4) Information to subjects during trial  
The site will be offered a communication  package for the subject during the conduct of the trial. 
The package content is issued by [CONTACT_3454]. The communication package will contain written 
information intended for distribution to the subjects. The written information will be translated and 
adjusted to local requirements and distributed to the subject at the discretion of the investigator. The 
subject may receive a “welcome to the trial letter” and a “thank you for your participation letter” 
after completion of the trial. Further the subject ma y receive other written information during the 
trial.  
All written information to subjects must be sent to IRB/IEC for approval/favourable opi[INVESTIGATOR_17950].  
5) Data protection  
• Subjects will be assigned a [ADDRESS_931613] records or 
datasets that are transferred to Novo Nordisk will contain the identifier only; subject names or 
any information which would make the subject identifiable will  not be transferred.  
• The subject and any biological material obtained from the subject will be identified by [CONTACT_41163], visit number and trial ID. Appropriate measures such as encryption or leaving out 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  [ADDRESS_931614] t he identity of subjects as required by [CONTACT_5737], 
regional and national requirements.  
• The subject must be informed that his/her personal trial related data will be used by [CONTACT_156079]. The disclosure of the data m ust also be 
explained to the subject.  
• The subject must be informed that his/her medical records may be examined by [CONTACT_18024], by [CONTACT_6667]/IEC members, and 
by [CONTACT_336110]. [LOCATION_008]: For country specific requirements, 
please see Appendix 8 . 
6) Committee structure  
Novo Nordisk safety committee  
Novo Nordisk will constitute an internal safety committee to evaluate the ongoing safety of 
semaglutide. The safety committee may recomme nd unblinding of any data for further analysis, and 
in this case an independent ad hoc group will be established in order to maintain the blinding of the 
trial personnel.  
Data monitoring committee (DMC)  
The DMC is an independent, external committee compose d of members whose expertise cover 
relevant specialties including statistics. The DMC is established to review and evaluate accumulated 
data from the trial at predefined time points as well as ad hoc. This is done in order to protect the 
safety of the subj ects and to evaluate the benefit -risk balance. The DMC will have access to 
unblinded data, and will provide recommendations on trial continuation, modification or 
termination.  
Information regarding responsibilities, procedures and workflow to be used by [CONTACT_3433] e DMC are 
specified in the DMC charter.  
Event adjudication committee  
An independent external event adjudication committee (EAC) is established to perform ongoing 
blinded adjudication of selected AEs and deaths, see Table  9-1.The EAC will evaluate events sent 
for adjudication using pre -defined definitions and guidelines in accordance with the EAC Charter. 
The evaluation is based on review of pre -defined clinical data collected by [CONTACT_41166]. 
The EAC is composed of permanent members covering all required medical specialties. EAC 
members must disclose any potential conflicts of interest and must be independent of Novo 
Nordisk. The EAC will have no authorisations to impact on trial conduct, trial protocol or 
amendme nts. The assessment made by [CONTACT_687314] . 
The purpose of the adjudication is to confirm events in a consistent manner according to 
standardized criteria using independent external medical experts.  
The AEs f or adjudication are listed in Section 9.3. 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  [ADDRESS_931615] of experts from outside Novo Nordisk, and designated Novo Nordisk employees. The  
committee will operate under a charter agreed with Novo Nordisk.  
Global expert panel  
Global expert panel(s) (GEP) consisting of selected investiga tors and study coordinators, referred to 
as National Leaders (NL) and National Study Coordinators (NSC), respectively, will be formed. 
The panel members will discuss and provide global as well as local, guidance and advice on 
operational aspects of the tri al, including e.g. subject recruitment and retention topi[INVESTIGATOR_1102], as well as 
supporting peer -to-peer communication within the trial.  
7) Publication policy  
The information obtained during the conduct of this trial is considered confidential, and may be 
used by o r on behalf of Novo Nordisk for regulatory purposes as well as for the general 
development of the trial product. All information supplied by [CONTACT_687315] c onfidential 
information.  
No confidential information shall be disclosed to others without prior written consent from Novo 
Nordisk. Such information shall not be used except in the performance of this trial.  
The information obtained during this trial may be  made available to other investigators who are 
conducting other clinical trials with the trial product, if deemed necessary by [CONTACT_3454]. 
Provided that certain conditions are fulfilled, Novo Nordisk may grant access to information 
obtained during this t rial to researchers who require access for research projects studying the same 
disease and/or trial product studied in this trial.  
Novo Nordisk may publish on its clinical trials website a redacted CTR for this trial.  
One investigator will be appointed by [CONTACT_18036] (signatory 
investigator) on behalf of all participating investigators.  
Communication of results  
Novo Nordisk commits to communicate and disclose results of trials regardless of outcome. 
Disclosure includes publicatio n of a manuscript in a peer -reviewed scientific journal, abstract 
submission with a poster or oral presentation at a scientific meeting or disclosure by [CONTACT_11174].  
The results of this trial will be subject to public disclosure on external web sites acco rding to 
international and national regulations. Novo Nordisk reserves the right to defer the release of data 
until specified milestones are reached, for example when the CTR is available. This includes the 
right not to release the results of interim testing, because the release of such information may 
influence the results of the entire trial.  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  63 of 88 
 
At the end of the trial, one or more scientific publications may be prepared collaboratively by [CONTACT_1275](s) and Novo Nordisk. Novo Nordisk reserves the right  to postpone publication and/or 
communication for up to [ADDRESS_931616] intellectual property.  
In all cases the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. I n the event of any disagreement on the 
content of any publication, both the investigators’ and Novo Nordisk opi[INVESTIGATOR_17952].  
China : For country specific requirements, please see Appendix 8 . 
Authorship  
Novo Nordisk will work with one or more investigator(s) and other experts who have contributed to 
the trial concept or design, acquisition, analysi s or interpretation of data to report the results in one 
or more publications.  
Authorship of publications should be in accordance with the Recommendations for the Conduct, 
Reporting, Editing and Publication of Scholarly Work in Medical Journals by [CONTACT_687316].27 
All authors will be provided with the relevant statistical tables, figures, and reports needed to 
evaluate the planned publication.  
Where required by [CONTACT_18038], the investigator from each trial site will be named in an 
acknowledgement or in the supplementary material, as specified by [CONTACT_18038].  
Site-specific publication(s) by [CONTACT_1697](s)  
For a multicentre clinical trial, analy ses based on single -site data usually have significant statistical 
limitations and frequently do not provide meaningful information for healthcare professionals or 
subjects, and therefore may not be supported by [CONTACT_3454]. Thus, Novo Nordisk may deny a 
request or ask for deferment of the publication of individual site results until the primary manuscript 
is accepted for publication. In line with Good Publication Practice, such individual reports should 
not precede the primary manuscript and should always  reference the primary manuscript of the trial.  
Investigator access to data and review of results  
As owner of the trial database, Novo Nordisk has the discretion to determine who will have access 
to the database. Individual investigators will have their ow n research subjects' data, and will be 
provided with the randomisation code after results are available.  
8) Dissemination of clinical trial data  
Information of the trial will be disclosed at clinicaltrials.gov and novonordisk -trials.com. It will also 
be di sclosed according to other applicable requirements such as those of the International 
Committee of Medical Journal Editors (ICMJE)28, the Food and Drug Administration Amendment 
Act (FDAAA)29, European Commission Requirements30, [ADDRESS_931617]  at 
these web sites, Novo Nordisk may disclose the investigator’s contact [CONTACT_18026]. As a 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  64 of 88 
 
result of increasing requirements for transparency, some countries require public disclosure of 
investigator names and their affiliations.  
The Primary Co mpletion Date (PCD) is the last assessment of the primary endpoint, and is for this 
trial Last Subject Last Visit (LSLV). The trial will therefore be registered with an estimated PCD 
corresponding to the estimated LSLV, which is first subject randomised pl us 61 months.  The PCD 
determines the deadline for results disclosure at clinicaltrials.gov according to FDAAA.  
9) Data quality assurance  
Case Report Forms (CRFs)  
• Novo Nordisk or designee is responsible for the data management of this trial including quality 
checking of the data.  
• All subject data relating to the trial will be recorded on electronic CRFs unless transmitted 
electronically to Novo Nordisk or designee (e.g. laboratory data). The investigator is responsible 
for verifying that data entries a re accurate and correct by [CONTACT_41174].  
• The following will be provided as paper CRFs:  
• Pregnancy forms  
• Other CRFs  
• The following will be provided as paper CRFs to be used when access to the CRF is revoked or 
the CRF is temporarily unavailable:  
• AE forms  
• Safety information forms  
• Technical complaint forms (also to be used to report complaints that are not subject 
related, e.g. discovered at trial site before allocation)  
• Corrections to the CRF data may be made by [CONTACT_36322]’s delegated 
staff. An audit trail will be maintained in the CRF application containing as a minimum: the old 
and the new d ata, identification of the person entering the data, date and time of the entry and 
reason for the correction. If corrections are made by [CONTACT_093]’s delegated staff after the 
date when the investigator signed the CRF, the CRF must be signed and dat ed again by [CONTACT_1275].  
• The investigator must ensure that data is recorded in the CRF as soon as possible, preferably 
within 5 working days after the visit. Once data has been entered, it will be available to Novo 
Nordisk for data verification and va lidation purposes.   
Monitoring  
• The investigator must permit trial -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source data documents (original documents, 
data and records). Direct access include s permission to examine, analyse, verify and reproduce 
any record(s) and report(s) that are important to the evaluation of the trial. If the electronic 
medical record does not have a visible audit trail, the investigator must provide the monitor with 
signe d and dated printouts. In addition the relevant trial site staff should be available for 
discussions at monitoring visits and between monitoring visits (e.g. by [CONTACT_756]).  
• Trial monitors will perform ongoing source data verification to confirm that data entered into 
the CRF by [CONTACT_18029], complete and verifiable from source 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  65 of 88 
 
documents; that the safety and rights of subjects are being protected, to monitor drug 
accountability and collect completed paper CRF pages, if applicable, and that the trial is being 
conducted in accordance with the currently approved protocol and any other trial agreements, 
ICH GCP, and all applicable regulatory requirements.  
• Monitoring will be conducted using a risk based approach including risk assessment , monitoring 
plans, centralised monitoring (remote assessment of data by [CONTACT_3454]) and visits to trial 
sites.  
• Monitors will review the subject’s medical records and other source data  to ensure consistency 
and/or identify omissions compared to the CRF.   
Protocol compliance  
Deviations from the protocol should be avoided. If deviations do occur, the investigator must 
inform the monitor and the implications of the deviation must be reviewed and discussed.  
Deviations must be documented and explained in a pr otocol deviation by [CONTACT_18030], date, 
and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed via edit checks in the CRF or via listings from the trial database.  
10) Source documents  
• All data entered in the CRF must be verifiable in source documentation other than the CRF.  
• The original of the completed PROs must not be removed from the trial site, unless they form 
part of the CRF and a copy is kept at the site.  
• Source documents provide ev idence for the existence of the subject and substantiate the 
integrity of the data collected. Source documents are filed at the trial site.  
• Data reported on the paper CRF or entered in the electronic CRF that are transcribed from 
source documents must be c onsistent with the source documents or the discrepancies must be 
explained. The investigator may need to request previous medical records or transfer records. 
Also, current medical records must be available.  
• It must be possible to verify subject’s medical  history in source documents such as subject’s 
medical record  
• The investigator must document any attempt to obtain external medical information by [CONTACT_41175](s) when information was requested and who was contact[INVESTIGATOR_530].  
• Definition of what constitutes sourc e data can be found in a source document agreement at each 
trial site. There will only be one source document defined at any time for any data element.  
11) Retention of clinical trial documentation  
• Records and documents, including signed informed consent f orms, pertaining to the conduct of 
this trial must be retained by [CONTACT_1732] 15 years after end of trial unless local 
regulations or institutional policies require a longer retention period. No records may be 
destroyed during the retention period  without the written approval of Novo Nordisk. No records 
may be transferred to another location or party without writte n notification to Novo Nordisk.  
Spain: For country specific requirements, please see Appendix 8 . 
• The investigator must be able to access his/her trial documents without involving Novo Nordisk 
in any way. If applicable, electronic CRF and other subject data will be provided in an 
electronic readable format to the investigator before access is revoked to the systems supplied 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  [ADDRESS_931618] data (in an electronic readable format or 
as paper copi[INVESTIGATOR_17951]) must be retained by [CONTACT_21655]. If t he provided electronic data (e.g. 
the CD -ROM) is not readable during the entire storage period, the investigator can request a 
new copy. A copy of all data will be stored by [CONTACT_3454].  
• Subject’s medical records must be kept for the maximum period permit ted by [CONTACT_5035][INVESTIGATOR_307], 
institution or private practice  
12) Trial and site closure  
Novo Nordisk reserves the right to close the trial site or terminate the trial at any time for any 
reason at the sole discretion of Novo Nordisk. If the trial is suspended or t erminated, the 
investigator must inform the subjects promptly and ensure appropriate therapy and follow -up. The 
investigator and/or Novo Nordisk must also promptly inform the regulatory authorities and 
IRBs/IECs and provide a detailed written explanation.  
Trial sites will be closed upon trial completion. A trial site is considered closed when all required 
documents and trial supplies have been collected and a trial site closure visit has been performed.  
The investigator may initiate trial site closure at an y time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a trial site by [CONTACT_41177]:  
• failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or local 
health authorities, Novo Nordisk procedures or GCP guidelines  
• inadequate recruitment of subjects by [CONTACT_093]  
• discontinuation of further trial product development  
Pre-planned inte rim testing may allow for premature termination of the trial.  
13) Responsibilities  
The investigator is accountable for the conduct of the trial at his/her site and must ensure adequate 
supervision of the conduct of the trial at the trial site. If any tasks  are delegated, the investigator 
must maintain a log of appropriately qualified persons to whom he/she has delegated specified trial -
related duties. The investigator must ensure that there is adequate and documented training for all 
staff participating in the conduct of the trial. It is the investigator’s responsibility to supervise the 
conduct of the trial and to protect the rights, safety, and well -being of the subjects.  
A qualified physician, who is an investigator or a sub -investigator for the trial, mu st be responsible 
for all trial -related medical decisions.  
The investigator is responsible for filing essential documents (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the data 
produced) in the investigator trial master file. The documents, including the subject identification 
code list must be kept in a secure locked facility so that no unauthorized persons can get access to 
the data.  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  [ADDRESS_931619] delegate responsibility for medical ca re of 
subjects to a specific qualified physician who will be readily available to subjects during that time.  
If the investigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires) a 
new investigator will be appointed in consultation with Novo Nordisk.  
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s).  
14) Indemnity statement  
Novo Nordisk carries product liability for its products, and liability as assumed u nder the special 
laws, acts and/or guidelines for conducting clinical trials in any country, unless others have shown 
negligence.  
Novo Nordisk assumes no liability in the event of negligence or any other liability of the sites or 
investigators conducting t he trial or by [CONTACT_18033].  
Belgium , [LOCATION_009]  and Mexico : For country  specific indemnity statements, please refer to Appendix 
8. 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
VV-CLIN-281603 1.0 .
VV-CLIN-281603 1.0 .
VV-CLIN-281603 1.0 .
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  [ADDRESS_931620] be recorded in the CRF whether female subjects are of childbearing potential.  
Definitions  
Woman of Childbearing Potential (WOCBP)  
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile.  
Women in the following categories are not considered WOCBP  
1. Premenarcheal  
2. Premenopausal female with one of the following:  
• Documented hysterectomy  
• Documented bilateral salpi[INVESTIGATOR_1656]  
• Documented bilateral oophorectomy  
Note: Documentation can come from the site personnel’s review of subject’s medical records, 
medical examination or medical history interview.  
3. Postmenopausal female  
• A postmenopausal state  is defined as no menses for 12 months without an alternative 
medical cause. A high Follicle Stimulating Hormone (FSH) level in the postmenopausal 
range may be used to confirm a postmenopausal state in women not using hormonal 
contraception or Hormonal Rep lacement Therapy (HRT). However, in the absence of 
12 months of amenorrhea, a single FSH measurement is insufficient.  
• Females on HRT and whose menopausal status is in doubt will be required to use one of the 
non-hormonal highly effective contraception met hods if they wish to continue their HRT 
during the trial. Otherwise, they must discontinue HRT to allow confirmation of 
postmenopausal status before trial enrolment.  
Contraception guidance  
Male subjects  
No contraception measures are required for male subj ects as the risk of teratogenicity/fetotoxicity 
caused by [CONTACT_156088].  
Female subjects  
Female subjects of childbearing potential are eligible to participate if they agree to use methods of 
contraception consistently  and correctly as described in table(s) below:  
 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  73 of 88 
 
Table  12-5 Highly effective contraceptive methods   
Highly  effective contraceptive methods that are user dependent a and b  
Failure rate of <1% per year when used consistently and correctly.   
Combined (oestrogen and progestogen containing)  oral, intravaginal or transdermal  hormonal contraception associated 
with inhibition of ovulation  
Progestogen only oral or injectable hormonal contraception associated with inhibition of ovulation  
Highly effective methods that are user independentb  
• Implantable progesteron only hormonal contra ception associated with inhibition of ovulation  
• Intrauterine Device (IUD)  
• Intrauterine hormone -releasing System (IUS)  
• Bilateral tubal occlusion  
Vasectomised partner  
A vasectomised partner is a highly effective contraception method provided that the partner is the sole male sexu al 
partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of 
contraception should be used.   
Sexual abstinenceb 
Sexual abstinence is considered a highly effective method only if defined as refraining  from heterosexual intercourse 
during the entire period of risk associated with the trial product. The reliability of sexual abstinence needs to be 
evaluated in relation to the duration of the trial and the preferred and usual lifestyle of the subject.   
Notes:  
aTypi[INVESTIGATOR_35818]. Use should be consistent with 
local regulations regarding the use of contraceptive methods for subjects participating in clinical trials.  
bContraception should b e utilised during the treatment period and for at least  [ADDRESS_931621].  
In certain cases, it is accepted to use double barrier methods (a condom combined with an occlusive 
cap, e.g. diaphragm, with/ without the use of spermic ide). This should only be allowed:  
• in females with known intolerance to the highly effective methods mentioned above or where 
the use of any listed highly effective contraceptive measures are contraindicated in the 
individual subjects, and/ or  
• if the risk of initiating treatment with a specific highly effective method outweigh the predicted 
benefits of trial participation for the female subject.  
Justification for accepting double barrier method should be at the discretion of the investigator. The 
justification must be stated in the medical records.   
Argentina, Belgium,  [LOCATION_013] , Italy, Spain  and [LOCATION_008] : For country specific 
requirements, p lease see Appendix 8 . 
Pregnancy testing  
• WOCBP should only be included after a negative highly sensitive urine pregnancy test.  
• Additional urine pregn ancy testing should be performed at monthly intervals during the 
treatment period, if required locally ( Appendix 8 ). 
• Pregnancy testing should be performed whenever a menstrual cycle is missed or when 
pregnancy is otherwise suspected.  
• A urine pregnancy test must also be completed for WOCBP at the end of treatment  and follow -
up visits . 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  74 of 88 
 
Collection of pregnancy information  
Female subjects who become pregnant  
• Investigator will collect pregnancy information on any female subject, who becomes pregnant 
while participating in this trial.  
• Information will be recorded on the appropriate form and submitted to Novo Nordisk via secur e 
fax line, encrypted e -mail or courier within [ADDRESS_931622]'s 
pregnancy.  
• Subject will be followed to determine the outcome of the pregnancy. The investigator will 
collect follow -up information on subject and neonate, which will  be forwarded to Novo 
Nordisk. Generally, follow -up will not be required for longer than 1 month beyond the delivery 
date.  
• Any termination of pregnancy will be reported, regardless of foetal status (presence or absence 
of anomalies) or indication for proce dure.  
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy will be reported as an AE or SAE.  
• A spontaneous abortion is always considered to be an SAE and will be reported as such.  
• Any SAE occurring as a result of a post -trial pregnancy which is considered possibly/probably 
related to the trial product by [CONTACT_111433] [ADDRESS_931623].   
 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
VV-CLIN-281603 1.0 .
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  77 of 88 
 
Appendix 7  Retention of human biosamples   
In countries where allowed, the trial will involve collection of human biosamples to be stored in a 
central archive for future use as noted in Section 9.9. The following samples will be stored:  
• EDTA plasma (for future analyses of circulating biomarkers)  
• Urine  (for future analyses of urinary biomarkers)  
The samples will be stored at a secure central bio -repository after end of trial and until the research 
project terminates, but no longer than [ADDRESS_931624] withdraws from the biobank component all stored biosamples 
obtained from their own body will be destroyed.  
Confidentiality and personal data protection will be ensured dur ing storage after the end of trial.  
In the event that the collected biosamples will be used in the future, care will be taken to target 
analyses within the scope defined in Section 9.9. 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  78 of 88 
 
Appendix 8  Country -specific requirements   
Argentina : 
• Appendix 5: Use of  barrier contraceptive method with spermicide in combination with another 
highly effective method as describe d in Table  12-5 is required for WOCBP.  
• Appendix 5:  Monthly testing with highly sensitive urine pregnancy tests  is required for 
WOCBP.  
• Novo Nordisk will reimburse costs of standard of care treatment for CKD ( angiotensin 
converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB)), pregnancy tests 
and contraceptive methods  
Belgium:  
• Appendix 3, section 14: Even if without fault, the sponsor is liable for the damage which the 
subject and/or his r ightful claimants sustain and which shows either a direct or an indirect 
connection with the trial (according to law concerning experiments on the human person of 07 
May 2004 - Article 29: §1).  
• Appendix 5 : Contraceptive measures considered adequate include highly effective contraceptive 
methods in accordance with the CTFG (Clinical Trial Facilitation Group) “Recommendations 
related to contraception and pregnancy testing in clinical trials ”, as listed in Table  12-5. This 
means that the use of double barrier methods is not applicable for Belgium.   
Brazil:  
• Section 6.2, exclusion criterion #4: Participation i n other trials within one year prior to 
screening visit (Visit 1) , unless there is a direct benefit to the research subject at the 
investigator's discretion  (according to Resolution 251/97, item III.2.j) . 
• Section 7.8: At the end of the trial, all participant subjects should be assured the access to the 
best proved prophylactic, diagnostic and therapeutic methods identified during the study  
(according to resolution CNS 466/12) . 
• Section 9.9: No subjects from Brazil will take part in the o ptional biob ank part of the trial  and 
no genetic testing will be performed . 
• Appendix 2: A ll laboratory results will be communicated to the investigators.  
• Appendix 3, section 3 : Two original i nformed consent form s will be sig ned and dated and one 
original will be given  to the subject (according to resolution CNS 466/12).  
• Novo Nordisk will reimburse costs of standard -of-care treatment for CKD.  
Bulgaria:  
• Collection of age is needed for the calculation of eGFR (CKD -EPI).24 
China:  
• Section 6.2, exclusion criteria  #4: ‘Simultaneous participation in a trial with the primary 
objective of evaluating an approved or non -approved investigational medicinal product for 
prevention or treatment of COVID -[ADDRESS_931625] has been received more than 30 days before 
screening.’ is not applicable for China.  
• Section 8.1, discontinuation/withdrawal criteria: ‘Simultaneous participation in a trial with the 
primary objective of evaluating an appro ved or non -approved investigational medicinal product 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  [ADDRESS_931626].’ is not applicable for China.  
• Section 9.1: Opt ional pre -screening is not allowed in China.  
• Section 9.9: No subjects from China will participate in the optional biobank part of the trial and 
no genetic testing will be performed.  
• Appendix 2: Laboratory samples for Chinese subjects will be destroyed acco rding to local 
regulatory requirement s, both for samples tested inside and  outside China.  No sample will be 
stored after the latest date of local regulatory approval.  
• Appendix 3, section 7: Information of the trial will be disclosed at clinicaltrials.gov, china, 
drugtrials.org.cn and novonordisk -trials.com, as China HA has requested to disclose trial 
information (phase 1 -3) at chinadrugtrials.org.cn since 2013.  
[LOCATION_009]  
• Appendix 3, section 14: The sponsor is responsible for identification of the harmful 
consequences of the biomedical the research for the person lending himself thereto and for 
indemnification of his beneficiaries, except in case of proof, incumbent on it, that the prejudice 
is not attributable to his fault or of the fault of any intervening pa rty, without the sponsor's being 
entitled to call on acts by a third party or the voluntary withdrawal of the person who had 
initially consented to cooperating in the research  (according to The French Public Health Code 
article L 1121 -10 (law n° [ADDRESS_931627] 
2004) . 
• Collection of age is needed for the calculation of eGFR ( CKD -EPI).24 
[LOCATION_013]:  
• Section 9.1: Optional pre -screening is not allowed in [LOCATION_013]  
• Appendix 5: Contraceptive measures considered adequate include highly effective contraceptive 
methods  in accordance with the CTFG (Clinic al Trial Facilitation Group) “ Recommendations 
related to contraception and pregnancy testing in clinical trials ”, as listed in Table  12-5. This 
means that the  use of double barrier methods is not applicable for [LOCATION_013] . 
• Subject's full date of birth is not allowed to be collected and must be shortened to year of birth. 
Collectio n of age is needed for the calculation of eGFR (CKD -EPI).24 
Hungary:  
• Collection of age is needed for the calculation of eGFR ( CKD -EPI).24 
India:  
• Section 9.5.3 : (additi onal clarifications in italics)  
Subjects with uncontrolled and potentially unstable diabetic retinopathy or maculopathy are not 
eligible as this indicates retinopathy that has recently progressed to a level that requires intervention 
or is approaching intervention,  but has yet to be brought under control.  A subject  with uncontrolled 
and potentially unstable retinopathy or maculopathy would be a subjec t that is not well -controlled 
in the sense that appropriate treatment and follow -up has not been receive d. 
Results of an eye examination performed by [CONTACT_687317] (e.g. optometrist) must be available and evaluated by [CONTACT_111419]. The eye examination shoul d be performed as a fundus 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  80 of 88 
 
photography (e.g. 2 -field 60 degree or better, colour or red -free) or by [CONTACT_41157] -lamp biomicroscopy 
examination (e.g. using a precorneal or corneal contact [CONTACT_41158]). Pharmacological pupil -
dilation is a requirement unless us ing a digital fundus photography camera specified for non -dilated 
examination.  
If the subject had such an eye examination performed within 90 days prior to screening, the 
investigator may base his/her evaluation upon the results of that examination. The e xamination must 
be repeated before randomisation if the subject has experienced worsening of visual function since 
the last examination. If the applicable eye examination was performed before the subject signed the 
informed consent form, it must be documen ted that the reason for performing the examination was 
not related to this trial.  
Each eye should be evaluated separately, and presence of the following should be assessed  and 
documented  
• Diabetic retinopathy – using the below staging:  
o Mild non -proliferati ve diabetic retinopathy (only microaneurysms)  
o Moderate -severe non -proliferative diabetic retinopathy  
o Proliferative diabetic retinopathy  
• Diabetic macular oedema  
• Impaired visual acuity (best corrected) – state Snellen grading if assessed  
Israel:  
• Section 9.9: No subjects from Israel will take part in the optional biobank part of the trial and no 
genetic testing will be performed.  
Italy:  
• Appendix 5: Contraceptive measures considered adequate include highly effective contraceptive 
methods in accordance with the CTFG (Clinical Trial Facilitation Group) “Recommendations 
related to contraception and pregnancy testing in clinical trials ”, as listed in Table  12-5. This 
means that the use of double barrier methods is not applicable for Italy. 
Japan:  
• Section 6.1, inclusion criterion #2: Male or female, age above or equal to 20 years at the time of 
signing informed consent.  
• Section 7.5: The head of the study site or the trial product storage manager assigned by [CONTACT_601701] (a pharmacist in principle) is responsible for control and accountability of the 
trial products.  
• Section 9.3 , Table 9 -1: For Japan all AEs,  irrespective of seriousness, should be collected from 
the day of randomisation and until the follow -up visit, at the time points specified in the 
flowchart. A non -severe non -serious hypoglycaemic epi[INVESTIGATOR_508067]. A 
severe non -serious h ypoglycaemic epi[INVESTIGATOR_508068] a 
specific event form (severe hypoglycaemic epi[INVESTIGATOR_1865]) should be filled out.  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  81 of 88 
 
• Appendix 3 , section  1: A name [CONTACT_687331] a signature.  
Mexico:  
• Section 8.2: Should the subject, his/her family members parents, or legal representative decide 
to withdraw the consent for participation in the trial, the subject will be entitled to receive 
appropriate, free of charge medical care and/or trial drug during the follow up period of the 
protocol wh en it will be established with certainty that no untoward medical consequences of 
the subject´s participation in the research occurred.  
• Appendix 3, section 1: The following responsibilities for the head of the Institution/Health Care 
Establishment, Ethics,  Research and, when applicable, Biosafety Committees and sponsor 
within their scope of responsibility:  
• Investigation follow -up. 
• Damages to health arising from the investigation development; as well as those 
arising from interruption or advanced suspension of treatment due to n on-attributable 
reasons to the s ubject . 
• Timely compliance of the terms in which the authorization of a research for health in 
human beings had been issued.  
• To present in a timely manner the information required by [CONTACT_135534].  
• Appendix 3, section 14 : 
• Novo Nordisk carries product liability for its products assumed under the special 
laws, acts/and/or guidelines for conducting trials in any country, including those 
applicable provisions on the Mexican [LOCATION_002]. If the subject  feels that 
something goes wrong during the course of this trial, the subject should contact [CONTACT_687318].  
• If during their participation in the trial the subject experiences a disease or injury 
that, according to the trial doctor a nd the sponsor, is directly caused by [CONTACT_687319]/or a trial procedure that otherwise would not have been part of 
his/her regular  care, the subject will receive from the institution or medical care 
establishment and free of charge, the appropr iate medical treatment as required. In 
this case, the costs resulting from such treatment as well as the costs of any 
indemnification established by [CONTACT_687320] s; even if the subject discontinues 
his/her participation in the trial  by [CONTACT_237209] a decision from the 
investigator.  
• By [CONTACT_79844], the subject will not renounce to any compensation 
or indemnification he/she may be entitled to b y law, nor will he/she will incur any 
additional expense as a result of his/her participation in the trial; any additional 
expense resulting from the subject’s participation in the trial will b e covered by [CONTACT_687321].  
Russia:  
• Appendix 3, section 1: The trial should be conducted in compliance with the protocol, Ministry 
of Healthcare of Russian Federation’ order #200н from April, 01, 2016 ”Approval of rules of 
good clinical practice” and legal requirements of the Russian Federation regul ating circulat ion 
of medicines.  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  82 of 88 
 
South Africa : 
• Section 9.9: No subjects from South Africa  will participate in the optional biobank part of the 
trial and no genetic testing will be performed.  
Spain:  
• Appendix 3, section 11: Records and documents, including signed informed consent forms, 
pertaining to the conduct of this trial must be retained by [CONTACT_1732] 25 years after end 
of trial.  
• Appendix 5: Contraceptive measures considered adequate in clude highly effective contraceptive 
methods in accordance with the CTFG (Clinical Trial Facilitation Group) “Recommendations 
related to contraception and pregnancy testing in clinical trials ”, as listed in Table  12-5. This 
means that the use of double barrier methods is not applicable for Spain.  
Turkey:  
• Section 9.9: No subjects from Turkey  will participate in the optional biobank part of the trial 
and no genetic testing will be performed.  
[LOCATION_008]:  
• Appendix 3, section 5: In the [LOCATION_008] the IRB/IEC does not have access to the patients’ 
medical records.  
• Appendix 5: Contraceptive measures considered adequate include highly effective contraceptive 
methods in accordance with the CTFG (Clinical Trial Facilitation Group) “Recommendations 
related to contraception and  pregnancy testing in clinical trials ”, as listed in Table  12-5. This 
means that the use of double barrier methods is not applicable for [LOCATION_008] . 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  [ADDRESS_931628] safety and data integrity 
during epi[INVESTIGATOR_303620]/pandemics (e.g. COVID -19)  
In case local restrictions due to an epi[INVESTIGATOR_901]/pandemic leads to lockdown of a site, the site must 
contact [CONTACT_1034] (Novo Nordisk) to allow for implementation of the mitigations mentioned in 
this appendix based on mutual agreement. Implementation of spec ific mitigations should be based 
on assessment of feasibility at the individual site.  
If local regulations, requirements and/or guidelines have been issued, these must be complied with.  
Assessments  
In case local restrictions due to an epi[INVESTIGATOR_901]/pandemic lea d to the lockdown of a site, site visits can 
be performed as home nursing. On -site visits are always preferred, but trial assessments can be 
performed by [CONTACT_687322]´s home  (or at alternative location)  if needed. As a pre -
requisite it must be ensured that trial site staff is covered by [CONTACT_197687]’ compensation insurance to 
protect workers. For all assessment s done at the subject´s home site specific equipment has to be 
used and procedures in the lab manual have to be followed. It must be do cumented in the medical 
records that the subject has consented to this process, and if any local requirements for informed 
consent applies, these must be followed. Home nursing may also be performed by a third -party  
nursing agency, if permissible by [CONTACT_1295].  
Trial product  alternative dispensing methods  
Alternative dispensing methods of study intervention may be implemented and details will be 
communicated and documented. The dispensing options will be based on options and requirements 
at country le vel and if permitted by [CONTACT_687323] A/S.  The trial product 
should be returned to the trial site or pharmacy when site is open and fully functioning again.  
 
 
 
 
 
 
 
 
 
 
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  84 of 88 
 
Appendix 10  Protocol amendment history   
Protocol amendment no. 1 (dated 24 January 2019, included in version 4.0)  
This amendment is considered to be substantial for Argentina based on the criteria set forth in 
Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European 
Union .[ADDRESS_931629] 
of care treatment costs will be reimbursed by [CONTACT_687324] 8, 
however this wording is not fully applicable due to the trial specific set -up: Novo Nordisk will 
reimburse standard of care for CKD (treatment with an angiotensin converting enzyme (ACE) 
inhibitor or an angioten sin II receptor blocker (ARB) in accordance with inclusion criteria # 6 ) and 
not for T2D in this trial.  
Section # and name  [CONTACT_687329] 8                            
Country -specific requirements for 
Argentina, amendment 1  Upda te of requirement: Novo Nordisk 
will reimburse costs of standard of 
care treatment for CKD (angiotensin 
converting enzyme (ACE) inhibitors 
or angiotensin II receptor blockers 
(ARB)), pregnancy tests and 
contraceptive methods  See overall rationale  
Protocol  amendment no. 2 (dated 03 June 2019, included in version 4.0)  
This amendment is considered to be substantial for [LOCATION_013] based on the criteria set forth in 
Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European 
Union.[ADDRESS_931630] of local HA  
Section # and name  [CONTACT_687329] 8                            
Country -specific requirements for 
[LOCATION_013], amendment 2  Update of requirement: Section 9.1: 
Optional pre -screening is not allowed 
in [LOCATION_013]  See overall rationale  
Protocol amendmen t no. 3 (dated [ADDRESS_931631] 2019, included in version 4.0)  
This amendment is considered to be substantial for India based on the criteria set forth in Article 
10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European Union .[ADDRESS_931632] Control Organisation (CDSCO), Office of 
Drugs Controller General (India).  
Section # and name  [CONTACT_687329] 8                            
Country -specific requirements for 
India, amendment 3  Additions to section 9.5.3  See overall rationale  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  85 of 88 
 
Protocol amendment no. 4  (03-November -2020)  
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union .[ADDRESS_931633] these changes.  
The sample size has been increased with 348 subjects.  
This amendment also addresses changes to the statistical tes ting strategy, as well as clarifications 
and administrative changes.  
Section # and name  [CONTACT_508117] [ADDRESS_931634] 
information is valid  
Section 2 Flowchart  Footnote “g” revised  To clarify when the collection of 
urine samples take place  
Section 2 Flowchart  Footnote “k” added  To clarify that yearly visits should 
take place approximately 13 weeks 
after the previous visit  
Section 3.2 Background  Backg round section has been 
elaborated  
 Background information expanded 
to provide expected population 
information captured by 
[CONTACT_156587]/exclusion criteria and to 
introduce communication options 
that may be used to motivate 
focused recruitment.  
Section 3.3.[ADDRESS_931635] the 
eGFR sample as primary endpoint 
event date. Detai ls on derivation of 
eGFR components in the presence 
of intercurrent events are given in 
the SA  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  86 of 88 
 
Section 6.2 Exclusion criteria  Addition to exclusion criterion 4 
*Simultaneous participation in a trial 
with the primary objective of 
evaluating an approved or non-
approved investigational medicinal 
product for prevention or treatment of 
COVID -[ADDRESS_931636] been tried  
Section 7.7 Concomitant medication  Text included for collection of 
COVID -19 concomitant medication  To specify that medication(s)in 
relation to a clinical  trial for 
COVID -[ADDRESS_931637] be recorded.  
Section 8.1 
Discontinuation/Withdrawal criteria  Text added to discontinuation 
criterion 3  
*Simultaneous participation in a trial 
with the primary objective of 
evaluating an approved or non -
approved investigational medicinal 
product for prevention or treatment of 
COVID -[ADDRESS_931638].   To allow for co -participation in a 
COVID -19 trial  
Section 8.1 
Discontinuation/Withdrawal criteria  Text revised  To clarify that subjects who 
participate in other trials can 
resume trial product if the 
investigational medicinal product 
of the other trial has been 
discontinued, if deemed safe by [CONTACT_687325].  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  87 of 88 
 
Section 8.1 
Discontinuation/Withdrawal criteria  Text regarding pregnancy updated  To specify that contracept ion 
should be utilised for at least [ADDRESS_931639] be 
performed by [CONTACT_2413].  
Section 9.2.1 Self -measure d plasma 
glucose  Text revised  To specify that subjects can use 
either their own BG meter or one 
provided by [CONTACT_687326].  
Section 9.2.2 Clinical efficacy 
laboratory assessments  Text regarding collection of 
creatinine values from medical 
records revised.  For clarification  
Section 9.3 Adverse events  Text regarding COVID -19 AEs 
included.  
‘including all fatal events’, 
pregnancies and technical complaints 
deleted on the list  To desc ribe the procedure for 
collection of COVID -[ADDRESS_931640] seriousness 
criteria. Hence there is no need to 
mention this here where it clearly 
states that all SAEs are collected.  
Pregnancies and technical 
complaints are not AEs and the 
collection and reporting of them is 
covered elsewhere in the protocol 
(section 9.3.7 and section 9.3.9, 
and Appendix 5 and 6).  
Section 9.3.1 Adverse events,   
Figure 2  Text regarding COVID -19 AEs 
included  To describe the proc edure for 
collection of COVID -19 AEs  
Section 9.5 Safety assessments  Addition of COVID -19 in text  To include COVID -19 to the 
concomitant illness/medical history 
that should be reported in the 
eCRF  
Section 9.5.3 Eye examination  Window for eye examination changed 
from 5 weeks to 8 weeks  To allow more time for performing 
eye examinations.  
Section 10.1 Sample size 
determination  The event rate for the nephropathy 
composite outcome in LEADER 
adjusted to 9.4%  To align with the population 
fulfilling the inclusio n criteria, 
including UACR<5000mg/g  
Section 10.[ADDRESS_931641] analysis on 
raw eGFR values  Log transformation is not 
considered necessary  in order to 
achieve the appropriate 
distributional properties.  
Section 10.3.1 Primary endpoint  Description of handling of missing 
eGFR data updated  Imputation of missing eGFR 
values is not considered necessary 
for the primary analysis.  
CONFIDENTIAL
VV-CLIN-281603 1.0 .
Protocol  
 Date:  25 January 2021  Novo Nordisk  
Trial ID: NN9535 -4321  Version:  5.0 
      Status:  Final  
      Page:  88 of 88 
 
Section [IP_ADDRESS] Confirmatory 
secondary endpoints  Updated text for the statistical testing 
strategy for the confirmatory 
secondary endpoints.  To preserve control of the type 1 
error for confirmatory endpoints.  
Section [IP_ADDRESS] Confirmatory 
secondary endpoints  Log-transf ormation prior to analysis 
of annual change in eGFR removed 
and baseline included as response 
variable.  Analysis will be done on raw 
eGFR value as it is not believed 
that log transformation is required 
in order to achieve the appropriate 
distributional pro perties.  
Section [IP_ADDRESS] Supportive 
secondary endpoints  Text revised  Specification of imputation model 
since  reference to primary analysis 
no longer appropriate after update.  
Section 10.3.4 Interim testing for 
efficacy  The requirement that 60% of the total 
primary endpoint events are renal 
events is removed  Requirement not considered 
necessary for valid interim results  
Appendix 2  Text revised  To specify that urine hCG 
pregnancy testing will be 
performed locally unless serum 
testing is required by [CONTACT_19566] l 
regulation or IRB/IEC.  
Appendix 2  hsCRP, Cholesterol, High density 
lipoprotein (HDL) cholesterol, Low 
density lipoprotein (LDL) cholesterol 
and Triglycerides moved to efficacy 
assessments  For correctness  
Appendix [ADDRESS_931642] safety 
and data integrity during 
epi[INVESTIGATOR_7509]/pa ndemics (e.g. COVID -
19) Implementation of mitigations (home 
nursing and alternative ways of 
dispensing) in case sites are locked 
down due to epi[INVESTIGATOR_7509]/pandemics 
(e.g. COVID -19) To ensure subject safety and data 
integrity in case of restrictions due 
to epid emics/pandemics (e.g. 
COVID -19) 
 
CONFIDENTIAL
VV-CLIN-281603 1.0 .